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INTRODUCTION Low  dose  carbon  monoxide  (CO),  a  byproduct  of  heme 
oxygenase, has been shown to cause vasodilatation, modify platelet adherence, reduce 
inflammation and inhibit apoptosis. Cardiac ischaemia-reperfusion (IR) injury occurs 
in patients with coronary artery disease and is also a common side effect of cardiac 
surgery.  Our aims were to study the effects of low dose inhaled CO administered 
continuously for 1 day prior to and 1 or 28 days after a cardiac IR injury, specifically  
carboxyhaemoglobin (COHb) levels, haemodynamics, markers of inflammation and 
mitochondrial electron transfer chain (ETC) function.
METHODS Lewis  rats  were  acclimatised  and  maintained  within  a  custom  built 
humidity, temperature controlled chamber. Rats inhaled gaseous CO at 20 parts per 
million (ppm) or air for 1 day prior to either a 30 minute left anterior descending 
artery  (LAD) ligation  and reperfusion  or  sham ligation  surgery.  CO delivery  was 
continued for 1 or 28 days post reperfusion until termination. An additional group 
received CO for 1 day following reperfusion and were then allowed to breathe room 
air without CO for 27 days. Arterial blood was sampled for COHb concentration and 
the rats sacrificed. Haemodynamics were immediately measured while the hearts were 
perfused  ex-vivo in  the Langendorff  mode.  Left  ventricular  peri-infarct  tissue was 
sampled  and  analysed  for  interleukin  (IL)1a,  IL1b,  IL2,  IL4,  IL6,  IL10,  tumour 
necrosis  factor  (TNF)-α,  and  granulocyte  macrophage  colony  stimulating  factor 
concentrations. Analysis of left ventricular mitochondrial ETC I, II,III and IV enzyme 
activities was performed in isolated freeze-fractured mitochondrial fractions. 
RESULTS There  was  a  significant  improvement  in  maximum  left  ventricular 
developed pressure (LVDPmax)  at  1  day and 28 days  following IR injury  in  the 
continuous  CO  treatment  groups  versus  control  (p  = 0.004  and p  =  0.005 
respectively). CO significantly attenuated the elevated heart rate observed in the air 
treated group 1 day following IR injury group (p = 0.002). Coronary blood flow was 
reduced in the air treated IR injury group at 28 days compared to sham intervention (p 
= 0.05). This injury induced flow reduction was significantly attenuated by continual 
CO treatment (p = 0.07). CO also had an amplifying effect on early release of IL2, 
IL6  and  IL10  at  one  day  post  IR  injury  (p   =  0.005,  p   =  0.009,  p  =  0.0008 
respectively), and significantly increased the IL10 / TNF-α ratio at 1 day (p = 0.0006). 
While complex I activity was increased by CO treatment in the 1 day group there 
were  no  other  significant  differences  in  mitochondrial  ETC  in  this  model  as  a 
consequence of treatment or IR injury .
DISCUSSION We have shown inhaled CO at 20ppm reduces cardiac IR injury as 
measured by heart rate, LVDPmax and coronary artery flow in a rat heart model of IR 
injury.  Chronic  intervention  with  CO  gas  following  IR  injury  maintained 
cardioprotection over the healing phase and is superior to air exposure alone and also 
short term CO exposure (1 day before and 1 day after IR injury) when outcomes were 
measured at 28 days. 
We have demonstrated a CO-mediated modulation of the cytokine response to injury 
by massive upregulation of IL10 and an increase in the IL10 / TNF-α ratio which have 
beneficial  roles in modifying the detrimental effects of inflammation in cardiac IR 
injury.  Cardiac  energetics  were  difficult  to  analyse  within  the  peri-infarct  tissue 
sampled, however CO tended to increase Complex I activity in sham ligation groups 
at 1 and 28 days.
We postulate  that  low dose  CO may  offer  important  cardioprotective  benefits  to 
patients undergoing cardiac surgery associated with an ischaemic insult.
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1.1 General Introduction
It is somewhat ironic that the heart whilst having the entire circulating volume pass through it in just 
one minute is commonly afflicted by perfusion problems of its own.
Ischaemic heart disease is the biggest single killer of adults in New Zealand (Hay, 2004).Worldwide, 
an estimated 16.7 million people die annually from this disease (29.2% of total global deaths). 
Currently it is the leading cause of death in developed countries and the World Health Organisation 
predict it to become the leading cause in developing countries (WHO, 2008).
Coronary atherosclerosis is the principle causative factor of ischaemic heart disease. A degenerative 
condition often predisposed by family history and accelerated by smoking, diabetes, hypertension and 
dyslipidaemia. It causes non-occlusive then occlusive plaque to accumulate in the wall of the coronary 
artery resulting in chronic ischaemia, often manifesting clinically as angina. The vessel may suddenly 
occlude due to plaque rupture and thrombosis leading to acute ischaemia and infarction of  the 
myocardial  territory supplied by the affected  artery. Other causes of coronary occlusion are 
thromboembolism, coronary arteritis (eg. Kawasaki disease, polyarteritis nodosa), de Bakey Type I and 
II (Stanford A) aortic dissection, Luetic (syphilitic) aortitis involving ascending aorta and coronary 
ostia, congenital anomalous origin of coronary artery and an intramural course of the left anterior 
descending artery .
Reperfusion occurs when the  thrombosis is lysed before permanent damage has occurred, either by 
innate fibrinolysis or by therapeutic intervention. Reperfusion can lead to “cell salvage” or may 
actually  result in further injury due to the release of oxygen free radicals. Infarction of tissue occurs 
either by the direct effects of sustained acute ischaemia, or by apoptosis of injured cells (Scarabelli et  
al.,  2006). If survivable, infarcts heal by fibrosis to form non-contractile  and  potentially 
arrhythmogenic scar tissue (Fig. 1.1). 
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Ultimately, the site and size of the infarct and the cardiac reserve determines the clinical outcome. 
During the course of aging cardiac reserve is relentlessly undermined: an estimated 38 million myocyte 
nucleii disappear from the left and  14  million  from  the  right  ventricle each  year  (74%  of 
cardiacmyocytes  are  mononucleated,  25.5% binucleate  with  the  remainder  tri-  and  tetranucleated) 
(Olivetti  et  al.,  1996).  Cardiac wall thickness is maintained by progressive hypertrophy of  the 
remaining myocytes. Olivetti has called this process “the cardiomyopathy of the aging heart” (Olivetti 
et al., 1991) It was previously  thought that cardiomyocytes are terminally differentiated and do not 
regenerate, however there is increasing evidence that cardiomyocytes continue to be generated from 
stem cells beyond the early post-natal setting and into adulthood, albeit seldom  (Bergmann  et  al., 
2009). Strategies to prevent cardiomyocyte loss during coronary events will reduce the mortality and 
long term morbidity associated with ischaemic heart disease. Current therapies include pharmaceuticals 
such as aspirin, heparin, thrombolytics,  hydroxymethylglutaryl  coenzyme  A  reductase  inhibitors 
(statins), angiotensin converting enzyme (ACE) inhibitors and beta blockers, and interventions such as 
percutaneous coronary angioplasty, coronary artery bypass grafting and cardiac transplant. 
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Fig. 1.1: Sequalae in Cardiac Ischaemia Reperfusion Injury.
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Cardiac ischaemia reperfusion (IR) injury is a common side effect of cardiac surgery (Mentzer et al., 
2003).  During cardiopulmonary bypass, the aorta is  cross-clamped and  there are cycles of cardiac 
ischaemia and reperfusion. Typically, these are well tolerated because the energy demand of the heart 
is massively reduced by initiating cardiac arrest with cardioplegia, a solution that typically contains a 
potassium load (20mmol), is hypothermic (4°C), hyperoxaemic (pO 400mmHg)  and has  buffering 
properties (although there are significant variations between practices, e.g. warm blood cardioplegia, 
cross-clamp fibrillation). Reconstruction of the aortic arch may require the surgeon to perform deep 
hypothermic circulatory arrest resulting in whole body IR injury, the severity dependent on the period 
of arrest and temperature of the patient. In the field of transplantation, ameliorating or preventing organ 
IR injury is considered by many as the Holy Grail to improve early and late rejection phenomena.
Cardiac IR injury following cardiac surgery causes a range of patho-physiological disturbances with 
effects  manifesting clinically as minor aberrations to life threatening problems such as low cardiac 
output states (myocardial stunning), arrhythmia or infarction. Post-operative mortality can be increased 
even out to six months by IR injuries occuring peri-operatively detected by raised creatine kinase MB 
levels (Klatte et al., 2001). 
Presently there is no satisfactory way to replace lost cells excepting cardiac transplantation, which is 
greatly limited by donor availability and rejection. Human stem cell research to “create” myocardial 
repair has had limited results so far in clinical trials (Zweigerdt, 2007; Lee and Yau, 2009). 
1.2 Cardiac Biochemistry
1.2.1 Generation of ATP
Under normal conditions glucose is converted into pyruvate by the glycolytic pathway. Pyruvate enters 
the mitochondria and forms acetyl CoA, linking glycolysis with the citric acid cycle and oxidative 
phosphorylation.
3
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1.2.2 Glycolysis
One glucose molecule (C6) is converted into two pyruvates (C3) by a series of reactions with a net yield 
of 2 ATP and 2 NADH.
1.2.3 Formation of Acetyl CoA or lactate
In aerobic conditions, acetyl CoA is formed within mitochondria by the (oxidative) decarboxylation of 
pyruvate (Fig. 1.3). Acetyl Co A is key to initiating a chain of reactions known as the citric acid cycle 
(or Kreb's cycle). In anaerobic tissues, pyruvate is converted into lactate and NAD+, allowing only the 
glycolytic pathway to continue functioning (Fig. 1.4)
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                                                     2 CO2     Coenzyme A
               2 Pyruvate (C3)                                                 2 acetyl CoA
                                         2 NAD+                  2 NADH
                                            
                 Fig. 1.3:  Formation of Acetyl CoA
 C6             P-C6-P              2C3-P              2P-C3-P                                            2C3
  2ATP   2ADP                     2NAD+   2NADH  2ADP  2ATP     2ADP   2ATP
Fig. 1.2: Glycolysis
Pyruvate(C3) + NADH + H
+                           L-lactate + NAD+
Fig. 1.4: Formation of Lactate
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1.2.4 Citric Acid Cycle 
Acetyl CoA binds to oxaloacetic acid (C4) to form citric acid (C6). In a series of coupled reactions, 
citric acid is reduced releasing 3NADH, FADH2, ATP, 2CO2 and 3H+. These high energy molecules are 
then utilised in the electron transport system. (Fig. 1.5 (adapted from “Essential Cell Biology”, Second 
Edition published by Garland Science in 2004; by Bruce Alberts, Dennis Bray, Alexander Johnson, 
Julian Lewis, Martin Raff, Keith Roberts, and Peter Walter)).
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Key: components of the citric acid cycle
Pyruvic Acid (C3) Oxalosuccinic acid (C6) Fumaric acid (C4)
Cis-aconitic acid (C6) α-ketoglutaric acid (C5) Malic acid (C4)
Isocitric acid (C6) Succinic acid (C4) Oxaloacetic acid (C4)
6


















































































Chapter 1: INTRODUCTION        Low Dose CO and Cardiac IR injury
1.2.5 The Electron Transport Chain and Oxidative Phosphorylation 
The electron transport chain (ETC) is located on the inner mitochondrial membrane and consists of 
Complexes I-IV (NADH dehydrogenase, succinate-Q reductase, cytochrome b-c1 oxidoreductase, and 
cytochrome  oxidase  respectively).  These  are  large  protein  molecules  containing  metals  and  small 
organic  molecules.  Together  with coenzyme Q and cytochrome c they  act  as reducing agents  and 
electron carriers using NADH and FADH as substrates.
NADH  dehydrogenase  (Complex  I)  converts  NADH  +  H+  to  NAD+,  pumping  protons  into  the 
intermembrane space and passing electrons to co-enzyme Q-10. Succinate-Q reductase (Complex II) 
has a similar function utilising FADH. Cytochrome oxidase (Complex V) uses oxygen as the ultimate 
recipient for the electrons. 2.5 and 1.5 moles of ATP are produced per mole of NADH and FADH2 
respectively.
Complexes I, II and IV transfer protons from the mitochonrial matrix to the inter-membrane space. The 
matrix  becomes  negatively  charged  and  basic  compared  with  the  cytosol,  therefore  forming  a 
membrane potential and pH gradient across the inner membrane: the proton motive force (PMF). ATP 
synthase (Complex V) utilises the PMF to generate ATP from ADP and phosphate,  namely oxidative 
phosphorylation, see diagram below (adapted from “Biochemistry”, 5th edition; Jeremy M Berg, John 
L Tymoczko, and Lubert Stryer).
Fig. 1.6: (next page) The Electron Transport Chain
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1.3 Cardiac Physiology
1.3.1 Myocardial Oxygen Consumption and Coronary Blood Flow
Resting coronary blood flow to heart muscle is 0.9 mL/g/min. This accounts for 4 to 5% of the cardiac 
output, approximately 225mL/min rising by  three to fourfold increase during peak exercise. At rest 
approximately 60-70% of the oxygen is extracted from haemoglobin (Hb) in the coronary circulation, 
close to the physiological maximum.  Coronary  sinus  blood  typically  has  an  oxygen  saturation  of 
around 40% (Miyairi  et al., 1994). Therefore any increase in  demand for oxygen must be met by an 
increase in delivery via the coronary artery blood flow. 
The Hypothesis of Berne (1964) outlines the various factors that influence coronary artery blood flow: 
perfusion pressure, intramyocardial wall pressure, and importantly various metabolically active 
substances such as adenosine causing coronary vasodilatation (Berne, 1964). Berne later described how 
the cardiac nerves also  influence coronary blood flow: vagal stimulation leads to vasodilatation and 
increased flow, sympathetic stimulation leads to vasoconstriction which initially reduces flow but then 
this effect is overcome by an increase in local metabolic factors that lead to vasodilatation (Berne et al., 
1965).
In 1974 Gould described Coronary Flow Reserve as “the ability of the coronary vessels to increase 
blood flow in response to oxygen demands or as compensation for decreased oxygen carrying capacity 
of blood, or both.”  (Gould and Lipscomb, 1974).  Gould was the first to show experimentally that 
resting coronary artery blood flow is not reduced until stenoses exceed 85%, however stenoses of 30-
45% become flow limiting to maximal coronary flow, as required in times of exercise or stress. 
Coronary Flow Reserve is regulated by  vasodilatation / vasoconstriction, metabolic, neurogenic and 
endothelial mechanisms (Bradley and Alpert, 1991).
Myocardial oxygen demand or consumption (qO2), is proportional to the product of the heart rate and 
systolic blood  pressure  (Detry,  1996).  This reflects the amount of time the myofibres spend in 
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contraction and can also be measured by the area beneath the systolic portion of the pressure curve; the 
Tension-Time index (TTI) (Sarnoff et al., 1958).
1.3.2 Adenosine
Adenosine is formed from AMP by AMP 5-nucleotidase, primarily due to accumulation of ADP during 
ischaemia.  ADP would  ordinarily  be  converted  back  into  ATP but  can  be  converted  to  AMP by 
myokinase  (Rubio  et  al.,  1973).  Adenosine in the interstitium causes relaxation of arterioles by 
activation of A2A receptors via cyclic AMP activation, increasing coronary blood flow. Other cardiac 
functions of adenosine include negative chronotropy via the vagus, negative dromotropy, anti-β-
adrenergic and inhibition of platelet aggregation (Shryock and Belardinelli, 1997). Adenosine's effects 
on the heart are to realign the balance between supply and demand by increasing delivery but also by 
reducing myocardial oxygen demand. It has therefore become known as the “retaliatory metabolite” 
and its  effects  are  actually  similar  to  modern  cardiology strategies  for  the management  of cardiac 
ischaemia: reduce myocardial  work by reducing heart  rate and afterload (principally systolic  blood 
pressure)  thus  decreasing  the  TTI.  ADP  is  degraded  rapidly  by  the  endothelium  due  to  high 
concentrations  of  adenosine  deaminase,  nucleoside  phosphorylase  and  xanthine  oxidoreductase 
(Shryock and Belardinelli, 1997).
1.3.3 Nitric Oxide (NO)
Nitric oxide (NO, formerly known as endothelium derived relaxing factor) was originally discovered 
by Furchgott who with  Ignarro and Murad were later awarded the Nobel Prize in 1998 for their work 
concerning its  role as a signaling molecule in the cardiovascular  system  (Furchgott  and Zawadzki, 
1980). Vascular NO chiefly causes vasodilatation. It is also a potent inhibitor of platelet aggregation 
and  neutrophil  activation.  NO is  made  from L-arginine  by  nitric  oxide  synthase.  There  are  three 
isoforms of nitric oxide synthase: constitutive or endothelial (eNOS), inducible (iNOS) and neuronal 
(nNOS) (Umar and van der Laarse, 2010). eNOS is calcium dependent and is upregulated mechanically 
by  increased  blood  flow  or  pulsatility  and  chemically  by  acetylcholine,  adenosine,  bradykinin, 
substance P, ATP and ADP. iNOS is calcium independent and is upregulated by bacterial endotoxins, 
cytokines and interleukins. Although its basal activity is low, when stimulated iNOS can produce 1000 
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fold  greater  amount  of  NO than eNOS. nNOS is  found in  neural  tissue  and is  important  in  non-
adrenergic, non-cholinergic neural transmission.
NO exerts its effects in vascular smooth muscle cells by binding to and activating guanylyl cyclase 
which dephosphorylates  guanosine triphosphate (GTP) into cyclic-GMP. Cyclic-GMP reduces  Ca2+ 
influx,  activates  K channels  and  results  in  myosin  light  chain  phosphatase  activation  to  decrease 
vascular smooth muscle tone and increase vasodilatation (Hofmann et al., 2000) (Lincoln et al., 1994).
1.4 Pathogenesis of Ischaemic Heart Disease
1.4.1 Atherosclerosis
Cardiac IR injury is most commonly associated with atherosclerotic heart disease. There are  various 
theories for  the development of atherosclerotic plaques: (i) A type of lipid storage disease, this  has 
largely been abandoned. (ii) The response to injury hypothesis  (Ross  et  al.,  1977).  (iii) Infectious 
agents triggering formation of plaques (predominantly Chlamydia pneumoniae and cytomegalovirus) 
(Hsich  et al., 2001).  (iv) Platelet and/or fibrin deposits triggering atherosclerosis. (v) Physiological 
intimal thickening of the proteoglycan layer. (vi) Currently, the most widely accepted theory is of 
inflammation causing or promoting atherosclerosis and encompassing parts of the other theories 
(Hansson and Bondjers, 1980) (Libby and Theroux, 2005).
Endothelial cells are a heterogenous group of cells whose function may be altered by local paracrine 
effects or by disease states and injurious agents  (Stevens et al., 2001),  such as chemicals in cigarette 
smoke, hypercholesterolaemia, homocystinaemia, haemodynamic shear forces, hypertension, 
hyperglycemia, or the local effects of cytokines or viruses. Alterations  in  function  manifest  as 
vasoconstriction due to decreased production of NO, increased permeability to lipoproteins, expression 
of tissue factor leading to thrombosis, and expression of certain injury-induced adhesion molecules 
leading to adherence of platelets and inflammatory cells.
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The normal intima is composed of an endothelial layer at the luminal surface, an outer proteoglycan 
layer containing widely spaced smooth muscle cells, and  a musculo-elastic layer containing an 
abundance of smooth muscle cells and elastic fibres. The internal elastic lamina denotes the start of the 
media, although this is often absent at bifurcations, branch vessels and curvatures (Stary et al., 1992). 
Atherosclerotic plaques are asymmetrical thickenings within the intima of an artery. They occur in 
medium to large size vessels typically  at points of bifurcation and tight curves where there are 
increased shear forces from circulating blood, as in the response to injury hypothesis of atherosclerosis. 
Plaque growth tends to develop in an outward, “abluminal” manner initially; narrowing of the lumen 
only tends to occur once the disease is well established  (Libby  and  Theroux,  2005).  Coronary 
atherosclerosis chiefly  affects the epicardial vessels, sparing the intramural branches, however in 
transplanted hearts a form of accelerated atherosclerosis is often seen that is more diffuse, affecting the 
epicardial and intramural branches. Similarly, vein grafts that are placed in the arterial system as is 
common place in coronary artery bypass grafting develop an accelerated form of intimal thickening and 
atherosclerosis, not found in unadulterated veins.
1.4.2 The American Heart Association Histological Classification of 
Atherosclerosis
The American Heart Association has published a histological classification of atherosclerosis in their 
Report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. This divides the 
progressive development into six types, the first three being proposed as normal physiological changes 
present in most young people but also potential silent precursors to future disease (Stary et al., 1994):
• Type I lesion is an area within the intima where chemically detectable low density lipoprotein 
(LDL) has caused migration of macrophages and formation of scattered foam cells. These areas are 
more prominent at areas of “adaptive thickening” which are eccentric (non-obstructive) and represent 
vessel adaptation to stress present in all people.
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• Type II lesion is also known as the fatty streak which is visible on gross inspection. Microscopically 
it contains layered foam cells in the intima without the presence of lipid droplets and can be found in 
45% of infants in the first eight months of life. They may progress into fibrous plaques in later life or 
disappear (Faggiotto and Ross, 1984).
• Type III lesion contains extracellular collections of lipid particles in addition to the features above. 
It is known as the transitional or intermediate lesion towards forming atheroma.
• Type IV lesion contains a dense accumulation of extracellular lipid within a localised area of the 
intima. There is no major increase in fibrous tissue.
• Type V lesion is characterised by the development of prominent fibrous tissue. It has been 
subdivided into three subtypes: V(a) fibrous tissue is adjacent to a lipid core which may be single or 
multi-layered (fibroatheroma, multilayered fibroatheroma), V(b) the lipid core is calcified, V(c) the 
intima is replaced by fibrous connective tissue with minimal amounts of lipid.
• Type VI lesion describes a complicated plaque with disruption of its surface (Type VIa), with or 
without haematoma or haemorrhage (Type VIb) and thrombosis (TypeVIc). If a lesion demonstrates 
all three it may be labelled VIabc.
The first three types of atherosclerosis have detectable alterations in endothelial, intimal smooth muscle 
and macrophage biology, which become more exaggerated as a plaque develops:
1.4.3 Endothelial cells 
Endothelial cells become oriented away from the direction of flow, polyhedral or rounded in shape with 
increased stigmata and stomata, cilia and stress fibres (Goode et al., 1977) (Haust, 1987) (Taylor et al., 
1989).  There is an increase in the formation of multinucleated cells and demonstrable increased cell 
turnover and cell death  (Hansson  and  Bondjers,  1980) (Sjostrand,  1949).  Increased expression of 
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vascular cell adhesion molecule-1 (VCAM-1) and other cell signalling molecules leads to adherence of 
leucocytes  (Davis et al.,  2001) and platelet adherence via glycoprotein Ib and IIb/IIIa. There is an 
impairment of endothelial driven vasorelaxation and an increase in endothelial driven vasoconstriction 
via measurable decreases in endothelial derived relaxing factors (EDRF) such as nitric oxide and 
prostacyclin production (Chester et al., 1990) (Guerra et al., 1989) (Verbeuren et al., 1990).
1.4.4 Intimal smooth muscle
The original finding by Anitschkow in 1913 that intimal smooth muscle cells within atherosclerotic 
lesions demonstrate increased proliferation and become strongly basophilic, has subsequently shown to 
be associated with  increasing amounts of rough endoplasmic reticulum within the hyperplastic cells 
(Stary et al., 1994). The cells become synthetic phenotypes and produce type I and type III collagen, 
dermatan sulphate proteoglycan and stomelysin, factors that accelerate atherosclerotic plaque 
progression (Henney et al., 1991) (Jaeger et al., 1991). Additionally, cytokine production can increase 
factors such as granulocyte  macrophage colony stimulating factor (GMCSF), tumour necrosis factor 
alpha (TNF-α) and monocyte chemotactic protein-1 (MCP-1) (Barath et al., 1990) (Nelken et al., 1991) 
(Stary et  al.,  1994).  Lipoproteins also accumulate within the cytoplasm of these cells  (Hoff  et al., 
1991).
1.4.5 Macrophages
The major  step in the formation and progression of an atherosclerotic plaque is the accumulation of 
macrophages and their conversion into foam cells by the accumulation of lipoprotein derived 
cholesterol esters  (Rosenfeld  et  al.,  1991).  These cells induce the inflammatory response by the 
expression of MCP-1, GMCSF, TNF-α, interleukin  (IL)1, PDGF, adhesion molecules endothelial-
leukocyte  adhesion  molecule  (ELAM)-1, inter-cellular  adhesion  molecule  (ICAM)-1, the major 
histocompatibilty complex (MHC) class II antigens HLA-DR/DP, and  tissue factor  (Nelken  et  al., 
1991) (Rosenfeld et al., 1991) (Stary et al., 1994) (Wilcox et al., 1989).
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1.5 Pathophysiology of Cardiac Ischaemia Reperfusion Injury
1.5.1 Pathology of Cardiac IR Injury
1.5.1.1 Acute Ischaemia: Time Course
Occlusion of a coronary artery causes an almost immediate blanching followed by cyanosis of the 
myocardium. Within 10 seconds the ventricular wall contractions become impaired and bulge 
paradoxically outwards during systole. If ischaemia is relieved within 20 to 30 minutes then the 
damage will be largely reversible, although there will generally be a period of myocardial stunning for 
many hours. If occlusion persists beyond 30 minutes large numbers of myocytes will be lost. The 
subendocardial region is the most vulnerable area to ischaemia by coronary artery occlusion or 
systemic hypotension. The endocardium immediately next to the LV down to a depth of several 
hundred microns receives oxygen from blood within the LV cavity, and so is protected to a certain 
extent. 
Electron microscopy reveals the myoctye injury that occurs over the first 30 minutes of reversible 
ischaemia. There is sarcoplasmic reticulum and mitochondrial oedema, and glycogen is lost from the 
myocyte. After  30 to 60 minutes the injury becomes irreversible: the mitochondria swell further and 
amorphous matrix densities appear within them. Nuclear chromatin clumps on the periphery of the 
nucleus. The sarcolemma ruptures and proteins, such as myoglobin, lactate dehydrogenase, creatinine 
kinase, troponin I and T leak from the myoctye. 
By 24 hours changes are more obvious and are visible by  light microscopy. The myocytes become 
deeply eosinophilic and have the appearance of wavy fibres due to being stretched during systole. 
Coagulative necrosis occurs with characteristic changes in the nucleus of chromatin clumping and 
margination, pyknosis (nuclear shrinkage, becoming strongly basophilic), karyorrhexis (fragmentation 
of the nucleus across the sarcoplasm), karryolysis (extrusion of nuclear fragments from myocyte). 
Myocyte lysis occurs and by day 2 to 3 phagocytosis by polymorphonuclear (PMN) neutrophils on the 
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periphery of the infarct is occurring.  There is increasing interstitial oedema and small areas of 
haemorrhage.
By day 5 there are fewer PMN neutrophils but increasing numbers of macrophages, fibroblasts and 
lymphocytes. They are responsible for clearance of necrotic myocyte debris and laying down collagen, 
forming a scar. Granulation tissue appears at this stage (neovascularisation). From one to three weeks 
more collagen is steadily laid down. After four weeks the scar becomes denser with regression of the 
capillaries and inflammatory cells. This process may take longer in the centre of a large infarct due to 
the distances required for migration of cells and formation of granulation tissue from neighbouring 
vascularised tissue. In some cases necrotic myocytes are never removed and become “mummified” 
(McManus, 2008). 
1.5.1.2 Reperfusion
Reperfusion of an ischaemic zone of myocardium is essential for recovery, however it can create 
another process that initially  exacerbates myocyte injury and loss: reperfusion injury  (Lefer  and 
Granger,  2000).  Reperfusion may occur as  a  result  of  endogenous fibrinolytic processes or by 
pharmacological or procedural intervention, such as recombinant tissue plasminogen activator (rTPA) 
or percutaneous trans-catheter coronary angioplasty (PTCA) respectively. 
The main features of reperfusion injury histologically are areas of haemorrhage and the presence of 
contraction bands within necrotic myocytes. Contraction bands are formed by thickened Z bands in 
hypercontracted sarcomeres. Myocytes are triggered to contract by a heavy influx of Ca2+ through 
sarcolemma damaged by reactive oxygen species (ROS). Contraction band necrosis is also seen at the 
periphery of purely ischaemic infarcts where there is some degree of passive perfusion.
Restoration of perfusion leads to an intense inflammatory reaction with increased numbers of PMN 
neutrophils. Irreversibly injured myocytes under go coagulative necrosis and healing occurs by 
formation of granulation tissue in a similar way to purely ischaemic infarcts, but at an accelerated rate.
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1.5.2 Physiology of IR injury
1.5.2.1 Cardiac Ischaemia
During non-ischaemic conditions, protons are used by mitochondria for oxidative phosphorylation to 
provide the energy required for the actin and myosin filaments to contract, ATP is broken down to 
release  ADP,  inorganic phosphate (Pi) and a proton. Overall there is no net accumulation of protons 
within the cell. With the onset of ischaemia and cellular hypoxia, normal oxidative phosphorylation 
rapidly declines, and so the mitochondria's ability to use protons is impaired. ATP production becomes 
reliant on glycolysis and the phosphagen system. The glycolytic pathway is increased to provide ATP.
1.5.2.2 Reactive Oxygen Species and Oxidative Stress
Oxidative  stress  describes  a  condition  when  the  production  of  free  radicals  overcomes  the  innate 
antioxidant defences. ROS are the chief injurious agents involved in cellular injury and are produced 
during ischaemia and to a much greater extent during reperfusion (Lefer and Granger, 2000).The ETC 
within mitochondria is chiefly responsible for generating ROS, in fact superoxide (O2-) and hydrogen 
peroxide  (H2O2) are  continually  being  generated  and broken  down at  a  low level  (Dickinson  and 
Chang, 2011). Recent discoveries have demonstrated that these molecules have important physiological 
cellular signalling properties in cell proliferation, apoptosis and antioxidant gene regulation (Ray et al., 
2012). Superoxide dismutase (SOD) is a powerful antioxidant that helps to reduce “collateral damage” 
from these unstable molecules. 
1.5.2.3 Cytokines and the Inflammatory Response
In general, cytokines modulate the inflammatory response to cellular injury. Some cytokines are pro-
inflammatory, others have anti-inflammatory effects and some exhibit pleiotropic tendencies by their 
interactions (Dinarello, 2000). Both oxidative stress and activation of the classical complement cascade 
trigger TNF-α release which is generally regarded as responsible for initiating the cytokine cascade 
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(Frangogiannis et al., 2002). TNF-α levels tend to remain elevated throughout the myocardium during 
the healing phase and may play a role in preventing or delaying apoptosis in cardiac myocytes. 
IL8, together with C3a and C5a possess powerful leukocyte and T-lymphocyte chemotactic activity. 
IL8 stimulates neutophils to  de-granulate and also causes them to have a respiratory burst creating 
more ROS, potentiating the cascade.   IL1 levels typically peak at 1 day following myocardial injury. It 
does not have direct chemotactic  activity  but regulates  other aspects of the inflammatory response 
causing fever, growth and differentiation of B and T cells and induction of fibroblasts. Like IL1, IL6 is 
also involved in the acute phase response and can also cause differentiation of B cells and promotes 
ICAM-1 expression. ICAM-1 causes neutrophil adhesion and modulates cytotoxic neutophil release 
which can injure myocytes surrounding a necrotic area  (Jaeschke and Smith, 1997). IL1, TNFα and 
thrombin  have  been  shown  to  cause  endothelial  dysfunction  during  periods  of  oxidative  stress. 
(Gourdin  et al., 2009; Kleinbongard  et al., 2010). In the chronic setting, TNF-α and IL6 have been 
shown to be expressed in higher concentrations in patients with established heart failure (Shan et al., 
1997).
Early studies focusing on inhibiting the whole inflammatory response related to myocardial infarction 
by the administration of corticosteroids showed promising results in the laboratory (Libby et al., 1973), 
but was injurious in clinical practice  (Roberts et al., 1976), probably because of reduction in tissue 
repair mechanisms (Kloner et al., 1978; Reimer et al., 1993), and also increased risk of infection after 
major  surgery  (Marik  and  Flemmer,  2012).  To  date,  there  has  been  little  progress  in  the 
pharmacological modulation of the inflammatory response to injury, and the main focus in modern 
intensive care units  when treating  conditions  such as systemic  inflammatory  response syndrome is 
limitation of exacerbating factors and provision of supportive care. However, statins ACE inhibitors 
and  angiotensin  II  receptor  blockers  (ARB) have  demonstrated  some promising  anti-inflammatory 
characteristics and may have beneficial roles in this area  (Brull et al., 2002; Palaniyappan et al., 2009; 
Stumpf et al., 2009).
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1.6 Carbon Monoxide
1.6.1 Atmospheric CO production
CO gas is released naturally into the atmosphere as a result of emission from plants, oceans and 
wildfires. Man-made CO emissions occur primarily from the incomplete combustion of carbon-
containing compounds. Natural and anthropogenic production of CO from oxidation of methane and 
other hydrocarbons by hydroxyl radicals and ozone also account for a significant proportion of 
atmospheric CO.
1.6.2 CO poisoning
CO exposure is the leading cause of poisoning in the USA  (Valent  et al., 2002). It is a colourless, 
odourless, non-irritant gas. When released into an enclosed space it can accumulate and may rapidly 
lead to fatal poisoning. CO has an affinity for Hb 250 times greater than oxygen and readily displaces 
oxygen from myoglobin (Mb). 
The brain and heart are the most sensitive organs to hypoxia, due to their high oxygen demand. Central 
nervous system symptoms of CO poisoning are fatigue, headache, dizziness, disorientation, visual 
disturbance, nausea, vomiting, collapse and coma. Cardiac arrhythmias and pulmonary oedema herald 
cardiovascular collapse. Death will rapidly follow if immediate treatment is not provided.  CO 
exposure may also result in long term neuropsychiatric disorders occurring 2 to 28 days following 
exposure, which may be slow to resolve. Maternal exposure during pregnancy may cause foetal 
abnormalities and death.
CO causes tissue hypoxia by reducing oxygen transport on Hb by occupying binding sites, and 
impairing release of oxygen from Hb. It is estimated that when carboxyhaemoglobin (COHb)  levels 
reach 20-40%, intracellular cytochrome dependant oxidative phosphorylation is inhibited (Wittenberg 
and  Wittenberg,  1993).  Specifically,  CO inhibits cytochrome c oxidase (Complex IV of the 
mitochondrial respiratory chain)  (Alonso  et  al.,  2003).  This could lead to decreased mitochondrial 
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energy production and cellular dysfunction, particularly in organs with a high energy demand, such as 
the brain and heart. As with COHb, the effect can be measured in smokers and is reversible (Alonso et  
al., 2004).  Other proposed effects of CO poisoning include lipid peroxidation and formation of ROS 
that can injure neuronal tissue (Zhang and Piantadosi, 1992).
Once thought to be monophasic, the uptake and excretion of CO follows a biphasic pattern. This 
reflects the two “compartments” that CO occupies: circulating COHb in red corpuscles and muscle 
bound COMb. CO is absorbed or displaced from Hb before Mb can transfer CO to or from it. In the 
treatment of patients with CO poisoning, COHb levels can be unreliable as a toxicity marker as it does 
not reflect total body CO. Furthermore, a longer duration low level exposure, such as 160ppm CO for 
600 min will cause an identical COHb fraction (20%) as 10,000ppm for 5 min although the COMb 
levels differ greatly: 8.7% vs 1.8% respectively (Bruce and Bruce, 2006).
Therefore, CO is dangerous in both short term / high concentration exposure patterns and long term / 
low concentration patterns, as it will steadily occupy increasing numbers of Hb/Mb-oxygen binding 
sites. The latter has important implications for public health and workplace safety.
1.6.3 Carbon Monoxide and the Heme Oxygenase system.
The discovery that CO was made as a breakdown product of heme (Fe-protoporphyrin IX) degradation 
was made in 1949 by Sjostrand. By injecting heme into humans, increased amounts of CO gas could be 
measured in exhaled gas (Sjostrand, 1949). In 1969, Tenhunen discovered the enzyme heme oxygenase 
(HO) and showed it was a catalyst for the breakdown of heme into biliverdin IXα, Fe2+ and CO by 
cleaving the molecule at its α-methene bridge. The reaction requires NADPH and molecular oxygen 
and is inhibited by CO in vitro  (Fig. 1.7). The enzyme will  readily react with protohemin IX or 
methaemalbumin most readily and in decreasing levels of activity with methaemoglobin, the α and β 
chains of Hb, deuterohemin IX, coprohemin I, and the haemoglobin-haptoglobin complex. It does not 
react with oxyhaemoglobin, carboxyhaemoglobin, myoglobin or free porphoryins in vitro (Tenhunen et  
al., 1969).
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Since this discovery variants of HO enzymes have been found throughout many organisms, including 
cyanobacteria, algae and plants where it synthesises phytochromes required for photoreceptors and 
hence enables photomorphogenesis  (Davis  et  al., 2001).  In humans HO has two isoforms: HO-1 
(formerly heat shock protein 32) which is inducible (32K-Da in size) and HO-2 which is constitutive 
(non-inducible, 36 K-Da) (Maines, 1997). A third constitutive isoform has been isolated in rat neurons 
HO-3, but not yet in humans  (McCoubrey  et al., 1997).  HO-1 is found in a great variety of tissues 
including heart, liver, spleen and vascular endothelium. HO-2 is found in the brain and testes.
CO was long regarded as a toxic byproduct that was simply excreted via the lungs and as such has been 
used in physiological studies to measure the rate of heme degradation, as this is the main source of 
endogenous CO production in man (Awad, 2006). However, over the last 15 years there have been a 
number of exciting discoveries furthering our understanding of this reaction and the physiology of CO. 
In addition to heme, hypoxia induces synthesis of HO-1 by increasing mRNA synthesis (Maulik et al., 
1996).  ROS such as mitochondrial H2O2 and superoxide and cytosolic peroxidases (generated in 
vascular endothelial cells exposed to shear stress) also up regulate HO-1 expression (Han et al., 2009). 
HO-1 levels appear to peak at 12 hours of ischaemia  (Foresti  et al., 2001).  Most HO-1 is bound to 
smooth endoplasmic reticulum but has also been shown to cleave in response to hypoxia or hemin and 
translocates to the nucleus where it activates further cytoprotective transcription factors  (Liu  et al.,  
1997). HO-1 is also induced by statins, curcumin, UVA radiation and heavy metals, such as cadmium 
chloride and sodium arsenite  (Keyse and Tyrrell, 1989; Motterlini et al., 2000; Grosser et al., 2004; 
Chen et al., 2006). It can therefore be stated that HO-1 is involved in cellular protection mechanisms in 
response to a number of different stimuli.
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Biliverdin (and hence CO) synthesis from heme breakdown is increased during  hypoxia, but not to as 
great an extent  as the increase in HO-1 synthesis itself  (Foresti  et  al.,  2001).  The lack of oxygen 
required for the reaction to progress by oxidation of cytochrome P450 bound NADPH may account for 
this. It has been postulated that H2O2 can act as a substitute for oxygen in the heme catalytic reaction, 
allowing it to part-way progress even during severe ischaemia (Liu et al., 1997). However, increasing 
administration  of  the  substrate  hemin also  resulted  in  an increase in biliverdin formation even in 
hypoxic  conditions. Biliverdin is quickly reduced to unconjugated bilirubin which is a potent 
antioxidant, scavenging ROS and is  oxidised back to biliverdin. When bound to albumin in plasma 
biliverdin  prevents damage to albumin and lipid peroxidation of albumin bound fatty acids  (Stocker, 
2004). Biliverdin is reduced back to bilirubin in a redox cycle by biliverdin reductase, explaining why 
low concentrations of bilirubin can overcome 10,000-fold greater concentrations of oxidants, making it 
an extremely powerful and important antioxidant  (Baranano  et al., 2002). Experimental models have 
shown that increasing heme oxygenase activity  prior to myocardial  ischaemia by administration of 
hemin causes a reduction in infarct size; blocking the action of heme oxygenase by administration of 
Sn-protoporphyrin  abolishes  the  protective  effect,  however  exogenous  administration  of  bilirubin 
restored the protection (Clark et al., 2000).
1.6.4 Heme oxygenase and atherosclerosis
Interestingly,  increased  vessel  heme  oxygenase-1  (HO-1)  concentration  is  found  throughout  the 
development of atherosclerotic lesions, HO-1 mRNA is up-regulated in proportion to the amount of 
oxidised low-density lipoprotein (LDL) (Wang et al., 1998). HO-1 induction has been demonstrated to 
reduce monocyte chemotaxis into the intima of artery wall cocultures in response to oxidised LDL. 
Inhibition of HO-1 expression by pretreatment with pharmacological tools such as Sn-protoporphyrin 
IX  enhanced  chemotaxis.  The  authors  suggest  HO-1  has  a  protective  role  in  modulating  the 
development of atherosclerotic plaques through the antioxidants it produces via the breakdown of heme 
to biliverdin and bilirubin and therefore helps to maintain homeostasis of the vessel wall (Ishikawa et  
al., 1997).
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1.7 Physiology of Carbon Monoxide
1.7.1 Cyclic GMP (guanosine 3′,5′-cyclic monophosphate) activation
Both CO and NO cause activation of soluble guanylyl cyclase (sGC) resulting in increased levels of the 
second  messenger  cyclic GMP. Cyclic GMP is a very important activator of a great variety of 
intracellular functions by phosphorylating key intermediates  such as serine/threonine protein kinases, 
adenosine 3′,5′-cyclic monophosphate (cyclic AMP)-dependent protein kinases, protein kinase-
independent pathways, or by hydrolyzing cyclic GMP-specific phosphodiesterases (PDE)  (Tulis, 
2008). The type of cell will dictate the effect thus generated. 
CO like NO can react with sGC to  catalyse the transformation of guanosine triphosphate (GTP) into 
cyclic guanosine monophosphate (cGMP) (Sammut et al., 1998).  sGC is a heterodimeric heme enzyme 
with an α and β subunit. The heme moiety is located on the β subunit and the catalytic area is shared 
across both subunits. Binding of NO or CO to the heme moiety results in a conformational change that 
increases catalytic activity. It has been postulated that CO has a slightly different reaction with sGC to 
NO because CO activated sGC can only cause a 4 to 5 fold increase in cGMP production compared 
with NO activated sGC which increases production 400 fold (Zhang et al., 2008).
YC-1 is a synthetic chemical that can augment the sGC, cGMP response. A benzyl indazole derivative, 
it increases the affinity of the enzyme to GTP, stabilises the active form of sGC, prolongs binding of N) 
or CO to sGC and reduces the breakdown of cGMP by PDE  (Tulis,  2008).  It has been shown to 
amplify the response of CO-sGC binding to 100 fold activation of cyclic GMP  (Friebe  et al., 1996; 
Kharitonov  et  al., 1999).  It has been suggested that a naturally occurring chemical with similar 
properties may exist, giving the CO/HO system more credibility as an effective stress response system, 
like NO.
Various hormones such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type 
natriuretic peptide (CNP) and guanylin also cause production of cGMP by acting on membrane bound 
guanylyl cyclase (pGCs such as GC-A, GC-B and GC-C). These natriuretic peptides are released from 
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the heart in response to atrial stretch and cause vasodilatation, natriuresis and increased contractility via 
GC-A. They are typically elevated in patients with heart failure  (Hofmann  et al., 2000).  Guanylin is 
released in the intestine and causes Cl- secretion, increasing water loss from the gut via GC-C (Forte 
and Currie, 1995).
1.7.2 Vasodilatation
The vasorelaxant effects of CO have long been recognised. In 1952, Duke and Killick demonstrated 
CO-mediated reduction of pulmonary artery pressure in a cat model. They used pure CO or CO with 5-
10% CO2 inhaled gas mixture  with similar results  (Duke and Killick,  1952). The effect developed 
quickly after 30-90 seconds and disappeared after 3 minutes of stopping CO, long before the COHb 
levels returned to normal  (Duke and Killick, 1952).  Hypoxia induced by inhalation of pure nitrogen 
caused vasoconstriction. With accurate foresight, the authors stated “We can only suggest tentatively 
that CO may have combined with some haem compound other than haemoglobin, and that the 
inactivation of this compound resulted in a fall of pulmonary arterial pressure. We have no evidence on 
which to base either a suggestion of the identity of this compound, or of its location.”  Of course we 
now know that it is CO induced activation (not inactivation) of a heme containing compound (sGC) 
that has caused the observed effect.
Sammut et al. demonstrated the role of HO-1 in control of vascular tone: vasospasm was induced in 
isolated rat aortic rings by phenylephrine. The vasospasm was inhibited by upregulation of HO-1 in a 
nitric oxide independent fashion (Sammut et al., 1998). cGMP was found to be enhanced, leading to 
the conclusion that HO-1 had produced CO which caused vasodilatation via the sGC-cGMP pathway in 
the vascular endothelium. 
From work mainly focused on NO, it has been shown that cGMP release in vascular smooth muscle 
causes release of the serine/threonine protein kinase, cGMP dependent kinase (cGK) a major effector in 
the control of vascular tone via calcium (Ca2+). Intracellular Ca2+ causes smooth muscle contraction by 
phosphorylation of myosin light chains (MLC). cGK reduces intracellular Ca2+ through a number of 
mechanisms: (i) by causing phosphorylation of calcium activated K+ channels (BKCa). The activated 
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channel causes hyperpolarisation of the cell membrane by K+ efflux. This change in polarity closes a 
number of voltage sensitive membrane transport channels including L-type Ca2+ channels, reducing 
Ca2+ influx (Johnson and Lincoln, 1985). (ii) By interfering with inositol 1,4,5 triphosphate (IP3), a key 
molecule triggering release of intracellular Ca2+ from the endoplasmic reticulum and also influx via 
voltage dependant and independent Ca2+ channels  (Hofmann  et  al., 2000).  In addition 
dephosphorylating PP1M, a trimeric molecule with a myosin binding subunit (MBS) by cGK 
desensitises the MLC to Ca2+42. The MLCs have been described as undergoing “reverse contraction” ie 
vasodilatation and this has been induced in vitro by the cyclic GMP analogue 8-bromo cyclic GMP 
(Johnson and Lincoln, 1985).
A more recent study on human internal thoracic and radial arteries has confirmed and advanced these 
findings with CO; Achouh and co workers demonstrated that CO caused vasorelaxation in the presence 
of noradrenaline, a potent α  adrenergic agonist. Blocking NO gave the same degree of CO mediated 
relaxation. Interestingly, CO also worked equally well when the vessel endothelium was not intact and 
CO mediated relaxation occurred in arteries that had sGC completely blocked by 1H-
(1,2,4)oxadiazolow(4,3,-a)quinoxalin-1-one (ODQ). This was observed to occur more slowly, 
suggesting there is a second mechanism at work aside from sGC/cyclic GMP system (Achouh et al., 
2008).
Wang et al. demonstrated CO induced cyclic GMP independent vascular smooth muscle relaxation in 
rat tail arteries. In their experiment, cyclic GMP was blocked by Rp-8-Br-cyclic GMPS, and sGC was 
blocked by methylene blue. The degree of relaxation at various concentrations was significantly less 
and slower than in cyclic GMP active vascular strips, but did none the less  occur. This effect was 
abrogated by a large conductance calcium-activated K+ channel blocker, ChTx. Apamine, a blocker of 
small conductance BKCa had no effect on relaxation  (Wang  et  al.,  1998).  Therefore CO has been 
demonstrated to confer vasodilatation by two separate mechanisms; the cyclic GMP mechanism and by 
large conductance calcium-activated K+ channels.
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1.7.3 Thrombosis
CO has an inhibitory effect on platelet adherence and hence reduces thrombosis. In an allogenic aortic 
transplant model with HO-1 deficient mice, Chen et al. demonstrated that fatal thrombosis occurred in 
all subjects within 4 days. If CO was administered using CORM-2 (a second generation CO releasing 
molecule), survival significantly improved to 62% at 56 days (Chen et al., 2009). Mansouri and Perry 
showed that the platelet release of serotonin C by ADP, a key step in platelet activation, was inhibited 
in the presence of CO. This effect was also seen in blood samples taken from heavy cigarette smokers 
(Mansouri and Perry, 1984). Brüne and Ullrich also demonstrated that CO caused inhibition of platelet 
aggregation. In their experiment CO enhanced sGC activity 4 fold. CO had no effect on 
cyclooxygenase, thromboxane A2 synthase and 12-lipoxygenase. They concluded that CO acts on 
cGMP and a 25% increase in its level will cause inhibition of aggregation (Brune and Ullrich, 1987). 
In an experiment by True et al. using HO-1 knockout mice (HO-1-/-) undergoing photochemical carotid 
artery injury, thrombosis occurred more readily than in normal mice. Additionally they found 
administration of CO at 500 ppm for 24 hours prior to injury increased the time taken for thrombosis to 
occur in the knockout group from 21 hours to 37 hours (p < 0.05), but made no difference in the normal 
genotype mouse (HO-1+/+) (True et al., 2007). In the HO-1-/- group acute delivery of CO just before or 
during the injury did not confer any advantage.
1.7.4 Modulation of factors associated with ischaemic damage
Carbon monoxide has been shown to exert protective effects during ischaemic injury.  In a murine 
ischaemic lung injury model, Fujita et al. demonstrated that CO suppressed mRNA expression of 
plasminogen activator inhibitor (PAI-1), found mainly in mononuclear phagocytes, thereby 
encouraging fibrinolysis and resolution of ischaemia (Fujita et al., 2001). The authors concluded that 
CO conferred protection to the mice by inhibition of PAI-1 as CO did not give a survival benefit over 
mice genetically lacking in PAI-1. However, mice lacking tissue plasminogen activator suffered worse 
survival outcomes. The publication did not however report on whether CO improved survival in this 
group or not. In mice given ODQ, an inhibitor of sGC, CO did not exert its protective effects and did 
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not prevent ischaemic driven PAI-1 expression. NO caused similar results to CO and the conclusion 
was drawn again that CO primarily acted through the cyclic GMP system. 
In a Langendorff model of cardiac IR, Bak et al. demonstrated that HO-1 knockout mice had a lower 
threshold for developing ventricular fibrillation than homozygotes (HO-1+/+)) and heterozygotes (HO-
1(+/-)). They concluded that CO was mediating the arrhythmogenic effect as fibrillation occurred more 
frequently in the HO(+/+) and HO(+/-) groups, although CO was not directly tested in any groups (Bak et  
al., 2003).
1.7.5 Apoptosis
Patients with diabetes, acute coronary syndrome or impaired left ventricular function undergoing 
cardiac surgery appear to have elevated levels of apoptosis within their myocardium, as measured by 
the pro-apoptotic effect of samples of  their pericardial fluid  (Doi et al., 2004).  Apoptosis may also 
follow ischaemia and/or reperfusion as outlined previously.
In a study by Akamatsu et al, induction of HO-1 by administering cobalt protoporphyrin IX (CoPPIX) 
was demonstrated to confer protection to rat hearts undergoing cardiac transplant with prolonged (24 
hr) cold ischaemia. Blocking HO-1 with zinc protoporphyrin IX (ZnPPIX) was detrimental. However 
when CO was administered at 400ppm for two days prior to harvest in donor rats and two days post in 
recipients, the protection was restored. They also demonstrated a reduction in apoptosis in CO and 
CoPPIX treated groups  (Akamatsu  et al., 2004).  However they did not report if the protective effect 
remained in ZnPPIX treated rats given CO, as theoretically CO at 400ppm for two days may have 
caused significant tissue hypoxia sufficient to upregulate HO-1. Indeed CO has been shown to induce 
HO-1 in human umbilical vein endothelial cells  by upregulating the antioxidant transcription factor 
Nrf2 via protein kinase R-like endoplasmic reticulum kinase (PERK) (Kim et al., 2007).
Cardiomyocytes are richly imbued with mitochondria: approximately 23% of the cell volume is 
mitochondria,  by  comparison  skeletal myocytes contain  2%  by  volume (Kumar  et  al., 2008). 
Mitochondria can be compared to nuclear reactors in that they provide a tremendous amount of energy, 
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but if damaged can have disastrous local and distant effects. The mitochondrial permeability transition 
pore (MPTP) is a non-specific pore on the inner membrane of mitochondria (Halestrap, 2006). During 
normal physiological conditions the MPTP remains closed, but during periods of oxidative stress and 
calcium overload it can open, rendering the membrane permeable. The consequences of this are loss of 
the PMF within the mitochondria necessary to produce ATP, triggering cellular necrosis or apoptosis, 
by the intrinsic apoptotic pathway  (Halestrap,  2006,  2009;  Kroemer  et  al.,  2007). Mitochondrial 
membrane permeabilisation can be triggered by adenine nucleotide release (adenine, thymine, uracil, 
guanine), which is a feature of acute ischaemia. In a recent study by Querioga et al. using astrocytes, 
CO inhibited ischaemia induced apoptosis. In  this  study  CO reduced the loss of PMF, inhibited 
cytochrome-c release, and  prevented caspase-3 activation. The mechanisms proposed were CO 
generating intracellular ROS causing cellular preconditioning and CO induced glutathionylation of 
adenine nucleotides. The effect was demonstrated with a CO concentration of 50µM and interestingly 
was lost at 100µM (Queiroga et al., 2010).
Kondo-Nakamura et al. also demonstrated an anti-apoptotic effect of pre-dosing cardiomyocytes with 
CO that are to undergo ischaemia-reperfusion injury. They analysed phosphorylation of Akt which is 
one of the “pro-survival kinases” together with ERK and p38 MAP kinase, and are normally released 
after IR  injury. They showed CO caused generation of ROS within normoxic cells  which  was 
converted to H2O2 by SOD which phosphorylated Akt, suppressing apoptosis (Kondo-Nakamura et al., 
2010). Their proposed mechanism was demonstrated by Zuckerbraun et al: CO inhibits cytochrome-c 
oxidase (complex IV of the ETC) which allows “leakage” of small amounts of ROS. This effect was 
abrogated by administration of anti-oxidants and inhibition of complex III of the ETC (Zuckerbraun et  
al., 2007).
1.8 Study Design
There have been numerous studies from around the world focusing on the protective effect of CO in the 
realm of cardiac, lung and kidney transplant. Rui Wang, the doyen of CO physiology has coined the 
term “gasotransmitter” for CO together with nitric oxide and hydrogen sulphide (Wu and Wang, 2005). 
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We  hypothesised  that  prior  treatment  with  low  dose  CO  may  protect  myocardium  subjected  to 
ischaemia-reperfusion injury. This study examined the effect of very low dose inhaled CO at 20 parts 
per million (ppm) in a cardiac IR injury rat model of left anterior descending ligation and reperfusion. 
Within the realm of cardiac surgery, preventing or reducing the effect of IR injury is paramount to both 
the short and long term outcome of the patient. As most cardiac surgery is performed as an elective  
procedure, it affords the clinician time to administer pharmaceuticals to patients pre-operatively in the 
hope that this may improve outcomes. Therefore, in our project design, CO was administered for 1 day 
prior to IR injury and then for 1 or 28 days following it. Animals were harvested at either 1 or 28 days 
post  IR  injury  and  the  following  experiments  were  performed:  Langendorff  assessment  of 
haemodynamics,  measurement  of  coronary  flow,  serum  COHb  levels,  cytokine  analysis  and 
mitochondrial  ETC  analysis.  A  dose  of  20ppm  was  used  to  minimise  the  toxic  effects  of  CO 
accumulation in the long term exposure group. It is the lowest dose seen in the literature which still 
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2.1 Materials 
Inorganic and organic chemicals used in the following protocols were purchased from Sigma-Aldrich 
(Auckland,  New  Zealand)  or  BDH  laboratory  supplies  (Palmerston  North,  New  Zealand)  unless 
otherwise specified. Medical grade gases were obtained from BOC (Dunedin, New Zealand).
2.2 Animal Care
All experiments were approved by the University of Otago Animal Ethics Committee and procedures 
were carried out in accordance with their guidelines ‘The Care and Use of Laboratory Animals’ under 
ethics  permit  AEC  26/06.  Facilities  and  experimental  protocol  were  approved  by  the  University 
Veterinary Surgeon. Male Lewis rats (275-300g) were used due to their cardiac homogeneity. They 
were obtained from the University of Otago Hercus Taieri Resource Unit in Dunedin. After delivery, 
the animals were weighed and permitted to acclimatise for at least three days prior to any surgical 
intervention. Animals were housed in a standard air-conditioned room maintained at 25 ºC on a 12-hour 
light/dark cycle, and fed a standard rat diet and water  ad libitum. Selected animal(s) were fasted for 
twelve hours prior to anaesthesia and left anterior descending (LAD) artery ligation. Water was freely 
available during this time. 
2.3 Carbon Monoxide Exposure Chamber
A  CO  exposure  chamber  designed  to  house  up  to  thirty  rats  simultaneously  was  constructed  by 
adapting  a  hypoxic  chamber  that  had  been  built  chiefly  by  Dr  Ged  Davis  of  the  Department  of 
Physiology at the University of Otago. The chamber consisted of a fibreglass cabinet with an air-tight 
perspex door. An oxygen sensor prevented the oxygen levels falling below 18% by electronic linkage 
to a solenoid that activated a pump delivering atmospheric air into the chamber. CO2 was removed 
from  the  chamber  by  circulation  of  air  over  a  soda  lime  cannister. To  regulate  humidity,  a 
dehumidification circuit  extracted water vapour by cooling and condensation,  delivering water to a 
reservoir by an under-water sealed conduit. Relative humidity was maintained at 40%. The temperature 
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was controlled at 18 +/-2 0C. CO levels were maintained at 20ppm by a CO sensor linked via a solenoid 
to a cylinder of CO mixed with air at 2000ppm. As a safety feature, the floor of the chamber would 
open if there was a power failure, to safeguard against suffocation. Twelve hour day/night light cycles 
were maintained throughout. The chamber was only opened periodically for short periods to perform 
animal welfare checks and cage changes.
2.4 Cardiac Ischaemia-Reperfusion Injury Procedure
2.4.1 Anaesthesia
Anaesthesia was initiated by briefly exposing the rat  to halothane vapour in a glass belljar.  Endo-
tracheal intubation was performed by placing the animal supine and securing the upper incisors to the 
surgical bench with a loop of thread and tape. The tongue was retracted in an upwards direction to 
allow visualisation  of  the laryngeal  chords with a  laryngoscope.  A 16 gauge soft  plastic  uncuffed 
cannula was used to intubate the trachea. This was immediately connected to a small animal ventilator 
(SAR-830/P,  IITC Life  Science,  USA).  The  accuracy  of  endotracheal  intubation  was  assessed  by 
observing bilateral expansion and deflation of the chest with inspiration and expiration and noting the 
presence of carbon dioxide in expired gas using a capnograph. 
Anaesthesia was maintained by inhaled halothane (Merial New Zealand Ltd.) and nitrous oxide (BOC) 
mixed  with  air.  End  expiratory  gases  were  continuously  collected  and  analysed.  Oxygen  was 
maintained at  20%. Minimum alveolar  concentration  of  halothane  was kept  at  0.8-1,  ensuring full 
anaesthesia without overdose. Flow was maintained at 2.3ml tidal volume (50 breaths per minute) and 
toe pinch reflex used to assess depth of anaesthesia and ablation of pain reflex pathways.
2.4.2 Surgical Preparation
Surgical instruments scrubbed, washed and dried then immersed in 60% alcohol for 15 minutes. The 
operative field was sprayed with hibitane (Southern Medical, Dunedin, New Zealand). Strict aseptic 
techniques were maintained throughout the surgery.  Core body temperatures were carefully monitored 
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using  a  digital  thermometer  and  maintained  at  37.0±1°C  using  a  temperature  controlled  animal 
warming pad (Kent Scientific, USA).
The animal was prepared for surgery by taping three of its legs to the bench in a supine position. The  
fourth leg (back right) was left free to indicate immediately if anaesthesia became too light during the 
procedure. It was shaved over the anterior left chest and left groin area. The skin was prepped with a  
solution of 40% alcohol, and a sterile drape laid over. 
2.4.3 Femoral arterial cannulation
A cutdown of approximately 1.5cm. long was performed over the left femoral artery in the line of the 
groin crease.  Sub-cutaneous fat  was dissected to reveal  the femoral  vessels.  The common femoral 
artery was isolated proximal to the profunda femoris artery using careful dissection and looped with 7.0 
prolene. A transverse arteriotomy was performed and a flexible cannula (Tyco Electronics Pty Ltd, 
Australia)  inserted into the femoral artery, facilitating arterial blood sampling. The cannula was then 
removed and the femoral artery tied off above and below the arteriotomy. Blood flow to the leg was 
maintained via collaterals, especially the profunda femoris.
Arterial  blood  was  collected  in  a  heparin  coated  glass  capillary  tube  (Radiometer  Medical  A/S, 
Denmark)  and kept on ice while being transported to Dunedin Hospital Diagnostic Laboratories for 
immediate analysis. The sample was analysed for pH, pCO2, pO2, base excess, bicarbonate, COHb (%), 
Hb (g/dL) and haematocrit.
2.4.4 Left Anterior Descending Coronary Artery Ligation
An  anterior  thoracotomy  was  performed  at  the  level  of  the  fifth  left  intercostal  space,  which 
corresponds to a transverse line drawn from the midpoint of the sternum. The pectoralis major muscle 
was divided along its fibres to minimise injury and a retractor positioned to give adequate exposure. 
This facilitated inspection of the ribs and opening the fifth intercostal space by dividing the intercostal 
muscles on their insertion onto the upper border of the sixth rib. Great care was taken not to injure the  
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internal mammary artery that courses just lateral to the sternal border. The pleural cavity was opened 
and the lung retracted away. The pericardium was incised above the phrenic nerve to expose the heart. 
In the injury group, a 7.0 prolene suture (Ethicon,  Johnson & Johnson, New Zealand)  was placed 
around the LAD artery using the left atrial appendage as a landmark, and a soft plastic occluder applied 
to the suture.  The LAD artery was occluded for 30 minutes then released to allow reperfusion of the 
myocardium. In the sham group, the procedure consisted of identical steps up to and including opening 
the pericardium but without instrumentation of the heart; the chest was left open for the same time 
period as the injury group.
2.4.5 Wound closure and recovery from anaesthesia
Three figure-of-eight 5.0 prolene sutures were used to approximate the ribs, with the lung re-expanded 
by  using  positive  pressure  ventilation  and  a  temporary  drain.  The  animal  received  0.4mls  1% 
lignocaine to the wound and intercostal nerves. The pectoralis major was repaired using two figure of 
eight 5.0 prolene sutures  (Ethicon, Johnson & Johnson, New Zealand). The skin and subcutaneous 
tissues were closed using a running subcuticular 6.0 prolene suture and the ends buried so no suture 
was left exposed to irritate the animal. 
During skin closure the halothane was turned off. Upon completion of the surgery the nitrous oxide 
was turned off,  while  oxygenation  was maintained and the animal  allowed to wake.  After  careful 
weaning  from  the  ventilator  the  animal  was  extubated  and  returned  to  its  housing.  Frequent 
observations were made to check on the welfare of the rats.
2.5 Experimental Groups
Three  separate  treatment  groups  were  devised.  Controls  were  kept  in  air  and  sham  surgery  was 
performed on both control (air) and treatment (CO) groups:
The “1 day” subset received CO for one day prior to IR injury and then for a further one day after 
injury, then harvested, see Table 1 over the page.
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Group 1 day pre-procedure 
treatment
Procedure 1 day post procedure 
treatment
1AS Air Sham Air
1CS Air + CO 20ppm Sham Air + C0 20ppm
1A1 Air LAD ligation + 
reperfusion
Air
1CI Air + CO 20ppm LAD ligation + 
reperfusion
Air + CO 20ppm
Table 1: “1 day” subset
The “28 day” subset received CO for one day prior to IR injury and then for a further 28 days 
post procedure, then harvested, see Table 2 below.
Group 1 day pre-procedure 
treatment
Procedure 28 days post 
procedure treatment
28AS Air Sham Air
28CS Air + CO 20ppm Sham Air + C0 20ppm
28AI Air LAD ligation + 
reperfusion
Air
28CI Air + CO 20ppm LAD ligation + 
reperfusion
Air + CO 20ppm
Table 2: “28 day” subset
A “28 day short term exposure” subset received CO for one day prior to IR injury and then for a further 
full day, then returned to air and harvested at 28 days post procedure (27 days after being removed 
from the CO chamber), see Table 3 below.
Group 1 day pre-
procedure 
treatment





SCS Air + CO 20ppm Sham Air + CO 20ppm Air
SCI Air + CO 20ppm LAD ligation + 
reperfusion
Air + CO 20ppm Air
Table 3: “28 day short term exposure” subset
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The number of animals in each group calculated to achieve a statistically significant difference was 8. 
This was based on the results of previous work performed by Dr Sammut with a similar model (Suzuki 
et al., 2001).
2.6 Experiments
2.6.1 Confirmation of Infarct
To check the validity of the model and confirm the accuracy of injury, we collaborated with Dr Ian 
LeGrice's group from the University of Auckland's Bioengineering Institute. Picrosirus red staining and 
microscopy was performed on hearts from separate animals having LAD ligation without reperfusion, 
to confirm accuracy of the suture placement.
Briefly, the animal underwent LAD ligation as above but with a permanent suture. The animal was 
harvested  at  28  days  following  the  injury  and  the  heart  was  explanted.  The  ascending  aorta  was 
expeditiously  cannulated  and  retrogradely  filled  with  heparinised  saline  to  flush  blood  from  the 
coronary arteries and myocardial  tissue. Next it  was  perfused fixed in of Bouin’s Solution   by red 
picrosirus  acid  stain  and  bathed  overnight  in  10%  neutral  buffered  formalin.   The  hearts  were 
embedded  in  methacrylate  (Technovit®,  Electron  Microscopy  Services,  Hatfield,  PA,  USA). 
Sectioning (5  µm thick sections) and light microscopy was performed by Dr Ian LeGrice’s group in 
Auckland.
2.6.2 Cardiac Haemodynamic Assessment
At completion of the reperfusion time point, rats were removed from their specific housing conditions 
(CO chamber or air)  and swiftly transferred to the laboratory,  where they were anaesthetised with 
halothane by briefly placing them in a belljar as described above. Once anaesthetised the animal was 
removed,  breathing  spontaneously  within  a  loose  fitting  mask  containing  halothane  vapour.  A 
laparotomy was performed permitting ready access to the inferior vena cava. Blood (approximately 0.4 
mls) was drawn from the vessel and stored on ice for further analysis. Heparin (500 units) was then 
injected to fully anticoagulate the animal. The laparotomy incision was lengthened superiorly through 
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the chest wall, permitting isolation of the heart by dividing the pulmonary veins, superior and inferior 
vena  cava,  pulmonary artery  and aorta.  Care  was taken to  ensure a  generous length  of  aorta  was 
preserved. The heart was placed in a container of Krebs-Henseleit slush (40C) to allow further fine 
dissection and identification of the ascending aorta which was cannulated and secured by fine silk ties. 
It was then immediately cannulated and perfused in the Langendorff mode at a constant pressure of 
67.3mmHg  with  carbogen  (95% O2 and  5%  CO2)  gassed  Krebs-Henseleit  buffer  (118mM  NaCl, 
4.7mM KCl, 1.2mM MgSO4, 1.23mM KH2PO4, 24mM NaHCO3, 11mM glucose, and 1.2mM CaCl2 pH 
of 7.4.) at 370C as previously described (Sammut et al., 2001; Suzuki et al., 2001).
A deflated water-filled ventricular balloon (3-4 mm diameter) fabricated from cling film was placed 
into the  left  ventricle  by making an incision in  the left  atrial  appendage.  The balloon was passed 
through the appendage into the left atrium, through the mitral valve into the left ventricle. The balloon 
was  connected  via  a  Y-connector  to  a  graduated  spindle  syringe  containing  distilled  water  and  a 
pressure transducer, the system having been carefully de-gassed. A warming jacket was placed around 
the heart to reduce surface cooling which was left to equilibrate for 20 minutes.  Using a graduated 
syringe, distilled water was injected into the left ventricular balloon in 50µl increments to cause small 
increases in end diastolic volume and thereby pressure up to a maximum of 300µl. The end diastolic 
pressure  was  then  reduced  to  10mmHg  to  standardize  measurements.  These  measurements  were 
recorded  using  a  pressure  transducer  linked  to  an  electronic  interface  with  a  computer  running 
Chart™v4.2 software (AD Instruments, Castle Hill, Australia).
The  following  cardiac  haemodynamic  parameters  were  measured  using  techniques  thoroughly 
established in our laboratory: heart rate in beats per minute (bpm), maximum left ventricular developed 
pressure (LVDPmax) and maximum and minimum rate of pressure change (dp/dt max & dp/dt min) 
which are surrogates for contractility and compliance respectively.
Coronary flow was also measured with an end diastolic pressure of 10 mmHg by collecting effluent 
spilling from the explanted heart over a 30 second period and was recorded in ml/min.
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At the end of the haemodynamic assessment, the heart was removed from the rig. The LV apex was 
excised and snap frozen in liquid nitrogen and stored at -800C for pending analysis of inflammatory 
markers. The remainder of the LV was dissected out and prepared for mitochondrial isolation.
2.6.3 Cytokine Immunoassay
Snap frozen ventricular apex tissue was finely pulverised in liquid nitrogen. The crushed tissue was 
suspended in 500µl of a detergent based cell lysis buffer (supplemented with 2µl Factor 1, 1µL Factor 
2, (Bio-Plex Cell Lysis Kit, Bio-Rad, Laboratories Inc, NZ)  plus 2µl phenylmethylsulfonyl fluoride 
(PMSF) and 1µl protease inhibitor cocktail (Sigma)) and homogenized on ice using four strokes of a 
glass-teflon homogenizer (clearance 50μm). Homogenates were centrifuged at 13,000g in Costar Spin-
X microfilter (0.22µm) centrifuge and diluted initially to 5mg protein/ml in cell lysis buffer, then to a 
final  concentration  of  1mg/ml  with  rat  serum  diluent  (Bio-Rad  Laboratories  Inc,  NZ).  Cytokine 
analysis was performed by a multiplex suspension bead array immunoassay using a Bio-Plex 9-Plex 
assay kit (BioRad Laboratories Inc., NZ). Cytokine levels were assessed in 50µl homogenate using a 
Bio-Plex bead-array immunoassay kit (Bio-Rad Laboratories Inc., NZ) with a Luminex 100™ analyser 
(Luminex Corp., Austin, TX). Cytokine concentrations (pg.mg-1 protein) were calculated using Bio-
Plex Manager™ software from an internal standard curve (detectable range of 2 - 32,000pg/ml) for rat 
IL1a,, IL1b, IL2, IL4, IL6, IL10, TNF-α, and GMCSF.
2.6.4 Mitochodrial Electron Transfer Complex Analysis
2.6.4.1 Left ventricular homogenisation
The perinfarcted region from the LV free wall was isolated into ice cold Krebs-Henseleit buffer and 
minced finely with scissors in mitochondrial  isolation media (MIM)  (containing: 225mM mannitol, 
75mM sucrose, 10mM Tris base, 2mM EGTA; pH 7.2) on ice. During this period, 5mg of Nargase was 
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added, a proteolytic  enzyme to aid maximum recovery of mitochondria.  Then the minced LV was 
washed five times with fresh MIM to dilute the nargase.
The solution was then separated into two equal aliquots and each homogenized with a Glass-Teflon 
Potter Elvehjem homogenizer on ice. The homogenizer was run at 900rpm for the first homogenization 
and  then  repeated  at  1,100rpm.  This  was  then  repeated  for  each  sample  to  ensure  thorough 
homogenization.
2.6.4.2 Centrifugation
The two homogenates were centrifuged at 1,500g for 3.5 minutes at 4°C using a Beckman High Speed 
centrifuge. The supernatants were kept on ice and the pellets re-suspended in fresh isolation buffer and 
centrifuged at same condition for a further 3.5 minutes to collect all the mitochondria.
The supernatants were mixed and centrifuged at 11,000g for 12 minutes at 4°C. The supernatants were 
disposed of and the pellets were combined into one tube in isolation media and re-centrifuged at the 
same speed for a further 12 minutes in order to obtain a final pellet containing both sarcolemmal and 
interfibrillar  mitochondria.  Cardiac  mitochondria  prepared  applying  this  technique  had  previously 
shown no evidence of  lactate  dehydrogenase,  a marker of cytosolic  contamination (Sammut  et al., 
2001).
The mitochondria were re-suspended in 250µl of isolation buffer and homogenized with a 1ml hand 
homogenizer. Aliquots of isolated mitochondria were stored immediately at -80°C for measurement of 
mitochondrial  enzyme  activities  and  protein  concentration  as  previously  described  by  our  group 
(Sutherland et al., 2004).
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2.6.4.3 Mitochondria and Tissue Protein Assays
Mitochondria and tissue protein concentrations were measured using a commercially available protein 
assay (Lowry D.C. kit; Bio-Rad, UK): bovine serum albumin (BSA) was used to make up standard 
solutions of 0.1, 0.2,  0.3, 0.5,  1 and 1.5mM concentrations.  Each mitochondrial  and tissue protein 
sample was diluted by adding 2µl of sample to 98µl of isolation buffer. 5µl of diluted samples were 
then pipetted into a 96-well  plate  with the addition of 25µl of Reagent A (alkaline copper tartrate 
solution)  and  200µl  of  Reagent  B  (dilute  Folin  reagent).  Protein  samples  were  incubated  for  15 
minutes. Ultraviolet light absorbance values were read at 750nm at 21.5 ºC using a SpectraMax-Plus 
spectrophotometer  (Molecular  Devices,  Sunnyvale,  CA,  USA)  and  a  standard  curve  constructed. 
Sample protein concentrations were calculated using the dedicated SoftMax Pro v 4.6 kinetic software 
(Molecular Devices, Sunnyvale, CA, USA) and corrected for dilution factors.
2.6.4.4 Mitochondrial complex I analysis
Complex I activity was measured as the rate of NADH oxidation. A reaction mixture consisting of 25 
mM KH2PO4,  10  mM MgCl2,  0.2  mM NADH,  1  mM KCN (pH 7.2),  2.5mg BSA and  10µg  of 
mitochondrial  protein in  a  final  volume of 260µl was prepared.  The reaction  was initiated  by the 
addition of Coenzyme Q1 to give a final concentration of 50µM and light absorbance was measured at 
340nm for 5 minutes. An inhibited rate was then measured in the presence of 0.5mM rotenone for a 
further 5 minutes. Results were measured as the rotenone sensitive decrease in NADH levels expressed 
in nmol/min/mg protein.
2.6.4.5 Complex II, III assay
Complex II, III activity was measured as the antimycin A-sensitive rate of cytochrome  c reduction 
using a modified method described by King et al  (King, 1967). A reaction mixture consisting of 166 
mM KH2PO4, 15 mM EDTA, 0.8 mM cytochrome c and 100 mM KCN at pH 7.4 was made and 10µg 
of mitochondrial protein was added to give a final volume of 260µl. The reaction was initiated by the 
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addition of 20µl of 0.5M succinate, and light absorbance was measured at 550nm for 5 minutes. The 
inhibited rate was measured by the addition of 10µl of 1mM antimycin A for a further 3 minutes. 
Results were expressed as nmol/min/mg protein.
2.6.4.6 Complex V
Complex V activity was measured using a method modified from Soper and Pederson (1979), in order 
to perform the assay in a 96 well microplate reader. The reaction mixture contained 100mM Tris buffer 
pH 8.0 at 30°C, 1mM KCN, 100mM KCl, 6mM MgCl2, 10μM rotenone, 25U LDH, 25U pyruvate 
kinase, 5mM phosphophenol pyruvate, 0.3mM NADH made up to 225μl per well with milliQ water. 
10μg of mitochondrial sample was added to the reaction mix. Initiation of the reaction occurred by the 
addition of 5μL of 300mM ATP and the rate of the reaction was determined at 340nm at 30°C for 5 
mins. Inhibition of the reaction was achieved through the addition of 15μl 100μg/mL oligomycin and 
this rate was measured at 340nm at 30°C for 5 mins. Complex V activity was calculated and expressed 
as nmol/min/mg protein.
2.6.4.7 Citrate synthase assay
Citrate synthase activity was measured using a modification of a method described by Shepherd and 
Garland  (Shepherd  and  Garland,  1969).  Citrate  synthase  catalyses  the  release  of  CoA  from  the 
condensation  of  oxaloacetate  with  acetyl-CoA.  CoA formation  is  measured.  The  reaction  mixture 
contained 100mM Tris, 10mM Acetyl-CoA, 20mM dithionitrobenzoic acid (DTNB), 0.1% Triton X-
100 (pH 8.0), and 10µl of mitochondrial protein were added to give a final volume of two hundred 
sixty microlitres. The reaction was initiated by the addition of 10µl of 20mM oxaloacetate and light 
absorbance was measured at 412nm for 5 minutes. Results were expressed as nmol/min/mg protein.
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2.6.4.8 Standardisation of electron transfer complexes to citrate synthase
Due to the centrifugation process potentially isolating partially damaged as well as intact mitochondria, 
respiratory  chain  complexes  were  standardised  to  citrate  synthase  activity.  The  ratios  were  then 
compared  between  treatment  groups  to  examine  the  impact  on  electron  transfer  complexes  after 
accounting for differences in intact mitochondria (Scheubel et al., 2002; Clarkson et al., 2007).
2.7 Statistical Analysis
Two-way analysis  of  variance  (ANOVA) was used to  compare  groups with individual  differences 
discriminated  by  Tukey's multiple  comparison  of  means. Results  were  expressed  as  the  mean  ± 
standard error of the mean. Statistical significance was determined by a confidence interval of p < 0.05.
Individual outliers were examined and only removed in cases of extreme variation, or if a possible 
cause for error had been identified at the time of the experiment. Most outliers have been left in the 
analysis due to the relatively small size of individual subsets or because they still fall within the normal  
distribution of measurements. This practice avoids the criticism of “cleaning data” and gives an honest 
account of the variability inherent in both experimental method and biological systems particularly in 
diseased states.
Statistics  were  performed  using  the  R  statistical  language,  R  Core  Team  (2013).  Foundation  for 
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3.1 Confirmation of infarct 
3.1.1 Picrosirus red staining
Light  microscopic  analysis  of  picrosirus  red  stained  heart  28  days  post  permanent  LAD  ligation 
demonstrated full thickness myocardial infarction with wall thinning, LV chamber dilatation, loss of 
myocytes and scar formation (Figure 3.1).  This demonstrates the accuracy and validity of the LAD 
ligation model within our own laboratory, however it should be noted that permanent ligation was not 
part of the experimental protocol.
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 Figure 3.1: Picrosirus red-Bouin's staining of sections of infarcted ventricle. Cross-sections 
of left and right ventricle are shown. Extensive subendocardial and anterior trans mural scar 
is  clearly  demarcated.  There  is  ventricular  wall  thinning  and  chamber  dilatation. 
Interestingly,  there  is  less  infarction  involving  the  septum possibly  indicating  that  the 
ligation  occurred  distal  to  the  first  septal  perforator,  but  involvement  of  both papillary 
muscles.
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3.2 Carboxyhaemoglobin levels
Mean COHb levels increased significantly from baseline in CO treated animals  F7,64 = 9.9, p < 0.0001, 
however  there  was  no  evidence  of  increasing  accumulation  as  the  28  day  group  did  not  differ 
significantly from the 1 day group (Figure 3.2).
Figure 3.2 Carboxyhaemoglobin (COHb) levels within animals harvested at 1 or 28 days post IR injury or 
sham ligation surgery. COHb levels are significantly higher in CO exposed animals but there is no significant 
difference due to length of exposure.
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury
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3.3 Cardiac Haemodynamic Assessment
3.3.1 Heart Rate
3.3.1.1 1 day subset
Analysis of variance (ANOVA) showed that there were significant differences between the heart rate in 
the 1 day subset (ANOVA:  F3,34 =  6.04,  p = 0.002; Figure 3.3). There was a reduction in heart rate 
associated with CO administration within the IR injury group from 285 +/- 31 to 218 +/- 23 bpm (p = 
0.002). CO also reduced the heart rate in the sham group (1CS) to 225 +/- 26 bpm compared with air  
injury group (1AI) (p = 0.01).
3.3.1.2 28 day subset
There were no significant differences in heart rate  (ANOVA:  F3,44 = 0.4,  p = 0.75) between groups 
(Figure 3.3).
3.3.1.3 28 day short exposure subset.
There were no significant differences in heart rate (ANOVA:  F3,24 =   0.6, p = 0.6 ) between groups 
(Figure 3.3).
Key for Figure 3.3 (next page)
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SAS = air exposed group sacrificed 28 days following sham ligation; SCS = CO exposed group for 1 day  
prior and 1 day after sham ligation; SAI = air exposed group sacrificed 28 days following IR injury; SCI =  
CO exposure group for 1 day prior and 1 day after IR injury.
Special characters illustrate significant or interesting differences determined by Tukey's multiple comparison 
of means.
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Figure 3.3 CO administration causes a reduction in heart rate back to baseline 1 day following cardiac IR 
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3.3.2 Left Ventricular Maximum Developed Pressure
3.3.2.1 1 day subset
CO had a significant effect on LVDPmax at one day post injury (ANOVA:  F3,34 = 7.26, p < 0.001; 
Figure 3.4). Within the sham groups LVDPmax was 163 +/- 34 mmHg for air and 180 +/- 25 mmHg 
for CO (p > 0.05). LVDP max was depressed following injury within the air group (1AI) to 117 +/- 31 
mmHg (p = 0.008). CO treatment improved LVDPmax to control levels 171 +/- 29 mmHg (p = 0.004).
3.3.2.2 28 day subset
After  28  days  with  continuous  exposure  to  CO  there  were  persisting  significant  differences  in 
LVDPmax (ANOVA: F3,41 = 11.9, p < 0.001: Figure 3.4). The main reason for this was the injury group 
kept in air was impaired compared with the other three groups. CO treatment had improved LVDPmax 
within the  injury group from 108 +/-  39 mmHg (28AI)  to 154 +/-  27 mmHg (28CS)  (p = 0.01), 
however maximum developed pressure was not fully restored and remained significantly less than the 
air sham group (28AS) which was 211 +/- 44 mmHg.
3.3.2.3 28 day short exposure subset
Again, there were significant differences between the groups (ANOVA: F3,23 = 8.44, p < 0.001; Figure 
3.4). LVDPmax was significantly impaired in the air treated injury group 108 +/- 39 mmHg and short 
exposure CO injury group 146 +/- 31 mmHg compared to the air treated sham group 211 +/- 44 mmHg 
(p < 0.001, p = 0.02 respectively).
Key for Figure 3.4 (next page)
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SAS = air exposed group sacrificed 28 days following sham ligation; SCS = CO exposed group for 1 day  
prior and 1 day after sham ligation; SAI = air exposed group sacrificed 28 days following IR injury; SCI =  
CO exposure group for 1 day prior and 1 day after IR injury.
Special characters illustrate significant or interesting differences determined by Tukey's multiple comparison 
of means.
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Figure 3.4 Maximum Left Ventricular Developed pressure (LVDPmax) is increased by CO treatment at 1 day 
following IR injury (p = 0.004) and at  28 days following continuous exposure  to CO (p = 0.01).  Short  
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3.3.3 Contractility: dp/dt max
3.3.3.1 1 day subset
There were no significant differences in dp/dt max within this subset (ANOVA: F3,30 = 2.18, p = 0.1; 
Figure 3.5)
3.3.3.2 28 day subset
After 28 days there were significant variations in dp/dt max between groups (ANOVA: F3,44 = 3.5, p = 
0.02; Figure 3.5). The most significant of these was a reduction in dp/dt max in the air treated injury 
group (2535 +/- 1017 mmHg/sec) compared to air (3472 +/- 357 mmHg/sec, p = 0.09) and CO treated 
sham ligation (3425 +/-756 mmHg/sec, p = 0.03). There was a small but non-significant improvement 
in contractility by administration of CO (2894 +/- 703 mmHg/sec,  p = 0.6), but equally there was no 
significant reduction in contractility compared to air or CO treated sham ligation (p = 0.6 and p = 0.3 
respectively).
3.3.3.3 28 Day Short Exposure Subset
There were no significant differences between any of the groups (ANOVA: F3,27 = 1.59, p = 0.2; Figure 
3.5).
Key for Figure 3.5 (next page)
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SAS = air exposed group sacrificed 28 days following sham ligation; SCS = CO exposed group for 1 day  
prior and 1 day after sham ligation; SAI = air exposed group sacrificed 28 days following IR injury; SCI =  
CO exposure group for 1 day prior and 1 day after IR injury.
Special characters illustrate significant or interesting differences determined by Tukey's multiple comparison 
of means.
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Figure 3.5 There was a significant reduction in left ventricular contractility as measured by maximal increase 
in pressure over time (dp/dt max) at 28 days in the air treated IR injury group (28AI) compared to both sham 
ligation groups (28AS and 28CS, p = 0.09 and p = 0.03 respectively). Although continuous CO treatment did 
not significantly increase dp/dt max at 28 days over air treatment following IR injury (28CI vs 28AI, p = 0.6) 






Chapter 3: RESULTS        Low Dose CO and Cardiac IR injury
3.3.4 Diastolic Function:  dp/dt min
3.3.4.1 1 day subset
There were no significant differences between the groups (ANOVA: F3,30 = 2.11, p = 0.1; Figure 3.6)
3.3.4.2 28 day subset
There  was  a  trend  towards  impaired  diastolic  function  in  the  air  injury  group   (-1707  +/-  766 
mmHg/sec) compared with sham (-2347 +/- 173 mmHg/sec, p = 0.06; Figure 3.6). However there were 
no statistically significant differences overall between the groups (ANOVA: F3,44 = 2.36, p = 0.08).
3.3.4.3 28 day short exposure subset
There were no significant differences between any of the groups (ANOVA: F3,27 = 1.49, p = 0.2; Figure 
3.6)
Key for Figure 3.6 (next page)
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SAS = air exposed group sacrificed 28 days following sham ligation; SCS = CO exposed group for 1 day  
prior and 1 day after sham ligation; SAI = air exposed group sacrificed 28 days following IR injury; SCI =  
CO exposure group for 1 day prior and 1 day after IR injury.
Special characters illustrate significant or interesting differences determined by Tukey's multiple comparison 
of means.
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Figure 3.6 There are no significant differences in rate of left ventricular diastolic function as measured by 
rate of pressure reduction (dp/dt min), however there was a trend towards impaired relaxation at 28 days in  
the air treated injury group (28AI) compared with the air treated sham ligation (28AS p = 0.06) 
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3.3.5 Coronary Blood Flow
3.3.5.1 1 day subset
There were no significant differences between coronary flow rates in the one day group. (ANOVA: 
F3,33 = 0.9, p = 0.4; Figure 3.7)
3.3.5.2 28 day subset
There were significant differences between coronary flow rates in the 28 day group (ANOVA: F3,33 = 
6.6, p = 0.001; Figure 3.7). The air injury group (28AI) had a coronary flow rate of 6.7 +/- 2.5 ml/min 
which was substantially lower than the air sham (28AS) group at 10.8 +/- 2.9 ml/min and the CO sham 
group (28CS) at 12 +/- 3.2 ml/min (p = 0.05, p < 0.001 respectively). The CO treatment injury group 
(28CI) had higher flows of 8.8 +/- 2.6 ml/min which was not statistically different from the sham 
groups nor the air injury group (p = 0.07).
3.3.5.3 28 day short exposure subset
Coronary blood flow was not recorded consistently in these groups.
Key for Figure 3.7 (next page)
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury
Special characters illustrate the p value for significant Tukey's multiple comparison of means.
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Figure 3.7 Coronary blood flow (mL/min) is significantly reduced after 28 days following IR injury in air 
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3.4 Inflammatory Markers
3.4.1 Interleukin 1-a (IL1a)
3.4.1.1 1 day subset
There were differences in IL1-a in the one day group (ANOVA: F3,13 = 3.7, p = 0.04; Figure 3.8), IL1-a 
was increased as a consequence of IR injury in both air and CO injury groups at one day against their 
respective sham intervention group, although did not reach statistical significance on indivdual Tukey's 
analysis (p > 0.05).
3.4.1.2 28 day subset
There were no significant differences between the groups  (ANOVA: F5,21 = 1.5, p = 0.2; Figure 3.8)
3.4.1.3 28 day short exposure subset
There were no significant differences between the groups  (ANOVA: F5,21 = 1.5, p = 0.2; Figure 3.8)
3.4.1.4 All group comparison
The aforementioned increase in IL1-a in both air and CO injury groups at 1 day in response to IR injury 
in both air and CO was accentuated (ANOVA: F9,34 = 3, p = 0.009; Figure 3.9)
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Figure 3.8 Interleukin 1-a (IL1-a) levels were not significantly altered by injury or treatment modality.
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Figure 3.9 Interleukin 1-a (IL1-a) levels were significantly increased 1 day after IR injury, CO administration 
did not have a significant effect on these levels.
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.4.2 Interleukin 1-b (IL1b)
3.4.2.1 1 day subset
There were significant differences between the groups (ANOVA: F3,13 = 7.0, p = 0.005; Figure 3.10). 
IL1-b was significantly increased in the CO treated IR injury group (1CI) at 3399 +/- 1659 pg/mL 
compared with sham ligation groups treated in air (1AS) and CO (1CS) at 781 +/- 75 and 587 +/- 195 
pg/mL respectively, but was not increased compared to air treated IR injury group (1AI) 2404 +/- 1748 
pg/mL, p = 0.6.
3.4.2.2 28 day subset
There were no significant differences between the groups  (ANOVA: F3,15 = 2.1, p = 0.1; Figure 3.10)
3.4.2.3 28 day short exposure subset
There were no significant differences between the groups  (ANOVA: F3,14 = 1.6, p = 0.2; Figure 3.10)
3.4.2.4 All group comparison
There were significant differences comparing all groups, (ANOVA: F9,34 = 5.5, p > 0.001; Figure 3.11). 
The aforementioned increase in  IL1-b in the 1 day CO IR injury  group was accentuated  and was 
significantly greater than all others except the 1 day air treated IR injury group, p ≤ 0.05 
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Figure 3.10 Interleukin 1-b (IL1-b) is significantly increased by CO treatment at 1 day following IR injury 
(1CI) compared with sham ligation in air (1AS) or CO (1CS) (p =0.008 and p = 0.01 respectively), but is not 
significantly  increased  compared  to  air  treated  IR injury  group (1AI),  p =  0.6.  There  are  no significant 
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Figure 3.11 CO treatment causes a significant increase in interleukin 1-b (IL1-b) levels at 1 day following IR 
injury (1CI) compared with all other groups except the 1 day air IR injury group (p ≤ 0.05). The air treated IR 
injury group had an increase in IL1-b levels at 1 day (1AI) compared to CO treated sham ligation (1CS) (p = 
0.03)
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.4.3 Interleukin 2
3.4.3.1 1 day subset
There was a significant increase in IL2 in the CO treated IR group at one day against the respective 
sham control (ANOVA: F3,13 = 8.4, p = 0.002; Figure 3.12)
3.4.3.2 28 day subset
There were no significant differences between the groups  (ANOVA: F3,15 = 0.6, p = 0.6; Figure 3.12)
3.4.3.3 28 day short exposure subset
There were no significant differences between the groups  (ANOVA: F3,14 = 1.8, p = 0.2; Figure 3.12)
3.4.3.4 All group comparison
Comparing different time intervals demonstrated significant differences between the groups (ANOVA: 
F9,34 = 20,  p < 0.0001; Figure 3.13). The main finding is a significant increase in IL2 in all 28 day 
groups when compared with the 1 day groups with the exception of CO treated IR 1 day group, which 
had already undergone a significant increase.
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Figure 3.12 Interleukin 2 (IL2) levels were significantly increased in the CO treated IR injury group at 1 day  
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Figure 3.13 Interleukin 2 (IL2) levels were significantly increased 28 days after sham ligation or IR injury 
regardless of air or CO treatment compared to the 1 day groups with the exception of the CO treated IR injury 
group (1CI) which has an early increase in IL2 levels (p < 0.001). The greatest increase in IL2 levels was 
found in the 28 day continuous and short term CO treated IR injury groups (28CI and 28SCI) and the 28 day  
short term CO treated sham ligation group (28SCS) which had IL2 concentrations significantly higher than all 
1 day groups (p ≤ 0.02)
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.4.4 Interleukin 4 (IL4)
3.4.4.1 1 day subset
IL4 concentrations  were significantly  reduced in the CO treated  sham group compared to  the CO 
treated IR group (166 +/- 116 vs 497 +/- 122 pg/mL, p = 0.03). This reduction approached statistical 
significance when compared to the air treated sham group (166 +/- 116 vs 526 +/- 273 pg/mL, p = 0.06) 
at  one  day  (ANOVA:  F3,10 =  5.8,  p =  0.01;  Figure  3.14). Summarising,  IL4 was reduced by CO 
treatment in sham operated animals but was maintained if the CO treatment was followed by the IR 
insult.
3.4.4.2 28 day subset
There were no significant differences between the groups  (ANOVA: F3,15 = 1.2, p = 0.4; Figure 3.14)
3.4.4.3 28 day short exposure subset
There were no significant differences between the groups  (ANOVA: F3,14 = 1.3, p = 0.3; Figure 3.14)
3.4.4.4 All group comparison
There were significant  differences between some of the groups  (ANOVA:  F9,31 = 5.8,  p < 0.0001; 
Figure 3.15). The most marked difference was the aforementioned reduction in IL4 in the 1 day CO 
treated sham group. IL4 concentration was most significantly elevated in the 28 day sham ligation air 
(28AS) and short exposure CO treated groups (28SCS) when compared to the lowest concentration 
which was found in the CO exposed sham group at 1 day (1CS), p < 0.001. The 1 day air exposed sham 
ligation group (1AS) had elevated levels as did the 1 day CO treated IR injury group (1CI) but were not 
statistically different from the other groups, p > 0.05.
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Figure 3.14 There is a reduction in interleukin 4 (IL4) levels in the CO treated sham ligation group at 1 day  
(1CS)  compared  to  the  CO treated  IR injury  group at  1  day  (1CI),  p =  0.03.  There  are  no  significant 
differences within the 28 day groups. 
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Figure 3.15 Interleukin 4 (IL4) concentration was most significantly elevated in the sham ligation air and 
short exposure CO treated groups at 28 days (28AS and 28SCS) when compared to the lowest concentration  
which was found in the CO exposed sham group at 1 day (1CS),  p < 0.001. The 1 day air exposed sham 
ligation group (1AS) had elevated levels as did the 1 day CO treated IR injury group (1CI) but were not  
statistically different from the other groups, p > 0.05.
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.4.5 Interleukin 6 (IL6)
3.4.5.1 1 day subset
IL6 concentrations  were significantly  increased in the CO treated IR group compared to  the other 
groups (ANOVA: F3,13 = 11.2, p = 0.0006; Figure 3.16)
3.4.5.2 28 day subset
There were no significant differences between the groups  (ANOVA: F3,15 = 0.1, p = 0.9; Figure 3.16)
3.4.5.3 28 day short exposure subset
There were no significant differences between the groups  (ANOVA: F3,14 = 0.1, p = 0.9; Figure 3.16)
3.4.5.4 All group comparison
There were significant differences between the groups (ANOVA: F9.34 = 6.9, p < 0.0001; Figure 3.17). 
IL6 concentrations were significantly elevated in all 28 day groups and the 1 day CO treated IR injury 
group (1CI) compared to the other 1 day groups; IL6 concentrations were similar between the 1 day 
CO treated IR injury group and all 28 day groups.
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Figure 3.16 Interleukin 6 (IL6) concentrations are significantly increased in the CO treated IR injury group at  
1  day  following  IR  injury  compared  with  all  other  1  day  groups,  p <0.003.  There  are  no  significant 
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Figure 3.17 Interleukin 6 (IL6) concentrations are significantly increased in all 28 day groups compared with  
the CO treated  sham ligation group at  1  day (1CS),  p  < 0.01.  CO treatment  significantly increases  IL6 
concentrations at 1 day following IR injury compared to all other 1 day groups, p < 0.02
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.4.6 Interleukin 10 (IL10)
3.4.6.1 1 day subset
IL10 concentrations were significantly increased in the CO treated IR injury group compared to all 
other 1 day groups (ANOVA: F3,12 = 10.5, p = 0.001; Figure 3.18)
3.4.6.2 28 day subset
There were no significant differences between the groups  (ANOVA: F3,15 = 2.0, p = 0.2; Figure 3.18)
3.4.6.3 28 day short exposure subset
There were no significant differences between the groups  (ANOVA: F3,14 = 0.3, p = 0.8; Figure 3.18)
3.4.6.4 All group comparison
There were significant differences between the groups (ANOVA: F9,33 = 9.0, p < 0.0001; Figure 3.19). 
IL10 was up-regulated in all groups at 28 days and in the CO treated IR injury group at 1 day.
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Figure 3.18 Interleukin 10 (IL10) concentrations are significantly increased in the CO treated IR injury group 
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Figure 3.19 Interleukin 10 (IL10) levels were significantly increased in all 28 day groups compared to the air 
treated IR injury group (1AI) at 1 day,  p < 0.01, and were most increased in the 28 day continuous CO 
treatment groups (28CS and 28CI)  p <0.001. CO treatment combined with IR injury caused an increase in 
IL10 levels over air treated IR injury at 1 day (1CI vs. 1AI), p = 0.04
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.4.7 Tumour necrosis factor alpha (TNF-α)
3.4.7.1 1 day subset
TNF-α  concentrations were significantly increased in the CO treated IR group compared to the air 
sham group (ANOVA: F3,13 = 4.1, p = 0.03; Figure 3.20)
3.4.7.2 28 day subset
There were no significant differences between the groups  (ANOVA: F3,15 = 1.5, p = 0.3; Figure 3.20)
3.4.7.3 28 day short exposure subset
There were no significant differences between the groups  (ANOVA: F3,14 = 0.3, p = 0.8; Figure 3.20)
3.4.7.4 All group comparison
There were significant differences between the groups (ANOVA: F9,34 = 5.3, p = 0.0001; Figure 3.21). 
The most striking difference was the reduction in TNF-α  concentrations in the 1 day air treated IR 
group.
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Figure 3.20 Tumour necrosis factor alpha (TNF-α) concentrations were elevated in the CO treated IR injury 
group at 1 day (1CI) compared to the air treated IR injury group (1AI),  p = 0.04. There were no significant 
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Figure 3.21 Tumour necrosis factor alpha (TNF-α) concentrations were significantly elevated in the 28 day 
groups compared with the 1 day air treated IR injury group (1AI) with the exception of 28AI, p <0.04. When 
comparing all groups, the increase in TNF-α seen in 1CI compared to 1AI is less significant p = 0.3.
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.4.8 Granulocyte macrophage colony stimulating factor (GMCSF)
3.4.8.1 1 day subset
There were no significant differences between the groups  (ANOVA: F3,7 = 2.0, p = 0.2; Figure 3.22)
3.4.8.2 28 day subset
There were no significant differences between the groups  (ANOVA: F3,15 = 2.5, p = 0.1; Figure 3.22)
3.4.8.3 28 day short exposure subset
There were no significant differences between the groups  (ANOVA: F3,14 = 1.9, p = 0.2; Figure 3.22)
3.4.8.4 All group comparison
There were significant differences between the groups  (ANOVA: F9,28 = 4.6, p = 0.0008; Figure 3.23). 
The most striking difference was the reduction in GMCSF in the 1 day CO treated sham group.
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Figure  3.22 Granulocyte  Macrophage  Colony  Stimulating  Factor  (GMCSF)  concentrations  did  not  vary 
significantly within groups.
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Figure 3.23  Granulocyte Macrophage Colony Stimulating Factor (GMCSF) concentrations were significantly 
decreased in the 1 day CO treated sham ligation group (1CS) compared to 28AS, 28CS, 28CI and 28SCS, p < 
0.03.
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.4.9 Ratio IL10 / TNF-α
3.4.9.1 All group comparison
There were significant differences between the groups at all time points  (ANOVA:  F9,33 = 11.2,  p < 
0.0001; Figure 3.24) IL10 / TNF-α ratio was significantly increased in all 28 day groups compared with 
the 1 day groups with the exception of the CO treated IR injury group which had already achieved an 
increased ratio comparable to the 28 day groups.
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Figure 3.24 There is a significant increase in IL10 / TNF-α ratio in all 28 day groups and the CO treated IR 
injury 1 day group (1CI) compared with the remainder of 1 day groups, p < 0.05
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.5 Mitochondrial Enzymatics
Results are expressed as nmol/min/mg protein and indexed against citrate synthase activity.
3.5.1 Complex I
3.5.1.1 1 day subset
Complex I activity was significantly increased in the CO treated sham group compared to air treated 
sham group (ANOVA: F3,20 = 4.2, p = 0.02; Figure 3.25).
3.5.1.2 28 day subset
There were significant differences between the groups (ANOVA: F3,16 = 3.3, p = 0.05; Figure 3.25), the 
most notable being an increase in complex I activity in the CO treated sham group.
3.5.1.3 28 day short exposure subset
There were no significant differences between the groups (ANOVA: F3,16 = 1.9, p = 0.2; Figure 3.25).
3.5.1.4 All group comparison
There were significant differences between the groups (ANOVA: F9,47 = 3.3, p = 0.003; Figure 3.26). 
The most striking effect was an increase in complex I activity in the groups with 1 or 28 days of  
continuous CO treatment following sham surgery.
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Figure 3.25 There was a significant increase in mitochondrial complex I activity in the CO treated sham 
ligation  group  (1CS)  at  1  day  compared  to  air  treated  sham ligation  (1AS).  There  were  no  significant  
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Figure 3.26 Complex I activity was significantly increased in 1 and 28 day CO treated sham ligation groups  
compared to the 1 day air treated sham ligation group, p <0.01.
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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3.5.2 Complex II,III
3.5.2.1 1 day subset
There were no significant differences between the groups (ANOVA: F3,20= 0.7, p = 0.6; Figure 3.27)
3.5.2.2 28 day subset
There were no significant differences between the groups (ANOVA: F3,20= 0.3, p = 0.8; Figure 3.27)
3.5.2.3 28 day short exposure subset
There were no significant differences between the groups (ANOVA: F3,16= 1.5, p = 0.2; Figure 3.27)
3.5.2.4 All group comparison
There were no significant differences between the groups (ANOVA: F9,47= 0.9, p = 0.5; Figure 3.28)
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Figure 3.27 There were no significant differences in complex II,III activities within the groups.
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Figure 3.28 There were no significant differences in complex II,III activities within the groups.
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
Special characters illustrate the p value for significant Tukey's multiple comparison of means.
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3.5.3 Complex V
3.5.3.1 1 day subset
There were no significant differences between the groups (ANOVA: F3,20= 2.5, p = 0.09; Figure 3.29)
3.5.3.2 28 day subset
There were significant differences between the groups  (ANOVA:  F3,16= 3.8,  p = 0.03; Figure 3.29), 
principally due to increases in complex V activity in the CO treated sham group.
3.5.3.3 28 day short exposure subset
There were significant differences between the groups  (ANOVA:  F3,16= 4.7,  p = 0.01; Figure 3.29), 
most notably an increase in complex V activity in CO treated injury group.
3.5.3.4 All group comparison
There were significant differences between the groups (ANOVA: F9,47= 4.2, p = 0.0005; Figure 3.30). 
The most striking difference was a significant increase in complex V activity in the 28 day CO treated 
sham group.
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Figure 3.29 There was a significant increase in complex V activity in the CO treated sham ligation group at  
28  days  (28AS)  compared  to  air  treated  sham ligation  (28AS),  p =0.05.  Complex  V activity  was  also 
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Figure 3.30 Overall, complex V activity was increased in 28CS and 28SCI groups.
Key for graphs
1AS = air exposed group sacrificed 1 day following sham ligation; 1CS = CO exposed group sacrificed 1 day 
following sham ligation; 1AI = air exposed group sacrificed 1 day following IR injury; 1CI = CO exposed 
group sacrificed 1 day following IR injury; 28AS = air exposed group sacrificed 28 days following sham 
ligation; 28CS = CO exposed group sacrificed 28 days following sham ligation; 28AI = air exposed group 
sacrificed 28 days following IR injury; 28CI = CO exposed group sacrificed 28 days following IR injury; 
SCS = CO exposed group for 1 day prior and 1 day after sham ligation; SCI = CO exposure group for 1 day  
prior and 1 day after IR injury.
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The  study  examined  the  effect  of  low  dose  (20ppm)  inhaled  CO  on  coronary  blood  flow,  left 
ventricular haemodynamics, cardiac cytokines and mitochondrial electron transfer complexes at 1 and 
28 days following IR injury. To our knowledge it is the first study to administer 20ppm CO gas for an  
extended period of time following IR injury. At this low dose this gaseous intervention paradigm was 
not associated with a toxic accumulation of CO: the maximum COHb levels of 2.25 +/- 0.4% recorded 
in the 28 day CO treated sham group, well below human toxic levels (Prockop and Chichkova, 2007). 
COMb levels were not measured directly but were unlikely to be higher than blood levels due to the 
lack of a significant concentration gradient.
CO treatment significantly reduced the heart rate in the 1 day IR injury group compared with the air 
treated IR injury group. Tachycardia in vivo may be a representation of increased sympathetic tone in 
response  to  an  ischaemic  or  injurious  state  (Aidonidis  et  al.,  1992),  however  in  an  effectively 
denervated  ex-vivo perfused  heart  model  this  is  unlikely  to  be  the  case.  Tachycardia  and  tachy-
arrhythmias are associated with irritability in peri-infarct zones  (Estner  et al., 2011; Arevalo  et al., 
2013) where changes in Na+, K+ and Ca2+ ionic channels affect the development of the cardiac action 
potential (Decker and Rudy, 2010). We hypothesise that the CO mediated reduction in tachycardia may 
represent a dramatic reduction in cellular injury and therefore better regulation of ionic channels, as 
demonstrated by Varadi and co-workers using a CO releasing molecule  (Varadi et al.,  2007). An 
alternative hypothesis is a possible anti-arrhythmic, rate control effect of CO administration, although 
we did not observe significantly slower heart rates in the CO group than in the air treated sham injury 
group.
CO had a protective effect on LVDPmax at both 1 and 28 days post IR injury when administered  
continuously; the effect was sufficient to maintain LVDPmax at sham levels in the 1 day group. After 
28 days of continuous CO exposure LVDPmax was significantly higher than the air treated IR injury 
group but was reduced compared with sham groups. This protective effect was not clearly seen in the 
28  day  short  exposure  CO subset,  suggesting  that  CO may  have  an  ongoing  role  in  maintaining 
myocardial function during the healing phase.
93
Chapter 4: DISCUSSION        Low Dose CO and Cardiac IR injury
The IR injury model was not sufficient to cause a significant reduction in contractility (dp/dt max) in 
either the air or CO treated groups as compared to sham ligation. This may in part be because there was 
considerable  variability  in  both  the  1  and  28  day  air  exposed  IR  injury  group.  There  were  no 
statistically significant differences detected in diastolic function between any of the groups, however at 
28  days  following  IR  injury,  continuous  CO  administration  compared  with  air  treated  animals 
demonstrated a strong trend towards improved dp/dt min (p = 0.06). Diastolic dysfunction following 
myocardial infarction is largely attributable to the detrimental effects of left ventricular remodeling, 
apoptosis and fibrosis causing decreased ventricular compliance and increased end-diastolic pressure 
and volume  (Beltrami et  al.,  1994). Heme oxygenase and CO have been shown to have protective 
effects during the healing phase, promoting reverse remodeling by inhibiting the opening of the MPTP 
thereby reducing apoptosis  (Queiroga et al.,  2010; Wang et al.,  2010). Statins, ACE inhibitors and 
ARBs have also been shown to have beneficial effects on diastolic dysfunction following myocardial 
injury, partly through modulation of the inflammatory cascade  (Palaniyappan et al., 2009; Stumpf et 
al.,  2009).  We  have  demonstrated  the  ability  of  CO  to  modify  the  inflammatory  response  most 
importantly  by  increasing  the  IL10  /  TNF-α  ratio  which  may  also  have  played  a  role  in  reverse 
remodeling, although most of the significant changes in cytokine concentration occurred at 1 day after 
IR injury and were not maintained during the late healing phase (28 days following IR injury).
Coronary flow was significantly diminished in the air treated IR injury group at 28 days compared to 
the sham groups. The CO treated IR injury group, although reduced, was not significantly different 
from sham ligation groups. The most likely explanation for reduced coronary flow in this model is 
occlusion of a coronary artery. There are three main coronary arteries (the LAD, circumflex and right  
coronary artery). As the flow was reduced to approximately two-thirds of the sham value (6.7 +/- 2.5 vs 
10.8 +/- 2.9 mL/min), this would substantiate loss of flow through one entire coronary artery territory. 
Temporary occlusion of the LAD artery may have resulted in damage to the intima of the blood vessel 
encouraging  vasospastic  and thrombotic  responses  to  occur  promoting  re-occlusion  in  spite  of  the 
mechanical resumption of coronary reperfusion. Protection of coronary flow following IR injury in the 
CO treated group may have resulted as a consequence of the fibrinolytic, anti-platelet and vasodilatory 
properties of CO as previously described (Sammut et al., 1998; Fujita et al., 2001; Bilban et al., 2008).
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Examination of the cytokine data shows that both IL1a and IL1b were elevated in the IR injury groups 
at 1 day and returned to lower levels by 28 days in all injury groups. CO increased IL1b levels to a 
significantly greater level than sham ligation when compared with the air treated IR injury group, but 
was not significantly higher than this group by itself. CO had no measurable effect on IL1a levels The 
results  obtained here demonstrate  appropriately how IL1 is involved in the acute phase reaction to 
injury, and return to low levels by 28 days following injury. IL6 has been described as being elevated 
in both the acute phase of IR injury, and in chronic heart failure (Jaeschke and Smith, 1997; Shan et al., 
1997). IL6 has been implicated in myocardial  ischaemic preconditioning by activation of the janus 
kinase (JAK) and signal transducer and activator of transcription (STAT) proteins  (Kurdi and Booz, 
2007; Boengler et al., 2008). The JAK-STAT pathway is an important second messenger system and is 
also activated by ROS and growth factors. It causes synthesis of DNA and has cardioprotective effects: 
a study of STAT3 knockout mice found enhanced susceptibility to cardiac injury (Hilfiker-Kleiner et 
al., 2005).  In this study, levels of IL6 levels peaked early only in the CO treated IR injury group, IL6 
levels were then uniformly elevated to a similar degree in all groups, correlating with a study by Moro 
and colleagues which demonstrated late increases in TNF-α and IL6 at day 8 following IR injury (Moro 
et al., 2007). Interestingly, a similar pattern emerges with IL2 and IL10: there is an increase across all 
groups at 28 days compared to the 1 day sham and air IR injury groups, but with CO causing an early  
significant increase in these levels only in the IR injury group.
There are similar but less clear cut patterns in the remainder of the cytokines studied: IL4, TNF-α and 
GMCSF. Here, there is a trend towards CO increasing levels in the IR injury group at one day, however 
there is also an unexpected elevation in the 1 day air treated sham group. In the 28 day groups IL4,  
TNF-α and GMCSF levels are generally elevated compared with the remainder of the respective 1 day 
groups.
The 28 day groups are interesting as with the exception of IL1a and IL1b there is almost uniform 
elevation of  myocardial cytokines regardless of myocardial injury status or CO administration at 28 
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days. As all the animals had invasive surgery, namely thoracotomy, opening of the pericardium and 
femoral artery cut-down, this may have caused a sufficient “whole body insult” to produce a systemic 
inflammatory response with widespread cytokine release during the period of the study. We did not 
measure baseline cytokine concentration in surgically naïve rats to correlate these values which may 
help to substantiate this claim.
IL10 may modulate  the deleterious  effects  of  TNF-α and other  pro-inflammatory  cytokines  and is 
associated with preservation of cardiac function following acute myocardial  infarction  (Kaur  et al., 
2006). We have demonstrated that CO has a powerful effect on increasing IL10 levels and the IL10 / 
TNF-α ratio acutely following myocardial IR injury. The almost four-fold increase in IL10 from 2697 
+/- 1685 to 9191 +/- 1798 pg/mL (p = 0.04) is so marked that there is a doubling of the IL10 / TNF-α 
ratio 4.7 +/- 1.9 to 10.3 +/- 1.0 (p = 0.0006) in the 1 day air injury compared with 1 day IR injury 
group. Losartan and atorvastatin have also been associated with increasing IL10 levels and the IL10 / 
TNF-α ratio following myocardial infarction with beneficial effects to cardiac remodeling (Kaur et al., 
2006; Stumpf et al., 2009).
In conclusion low dose CO gas inhalation appears to amplify IL10, IL6, IL2 and to a lesser extent IL1b 
release in the acute response to injury. The IL10 / TNF-α ratio was significantly increased by CO. CO 
did not appear to exert any ongoing effect on the cytokines levels that were analysed at 28 days.
The mitochondrial analysis revealed a CO mediated increase in complex I activity in sham groups at 1 
and 28 days which was not maintained in the IR injury group. Previous work with global IR injury in 
the myocardium had also shown that cardiac mitochondrial complex 1 activity could be upregulated in 
advance of an IR injury by heat stress treatment or specific transfection with heat shock protein 72 
(Jayakumar  et al.,  2000; Sammut et al.,  2001).There were no significant changes in complex II,III 
activity however, in any groups. Complex V activity exhibited some variability but most of this was 
due to a large amount of fluctuation in some of the 28 day results and is not easily explained. The lack  
of significance between study groups may reflect variability in tissue viability within the peri-infarct 
96
Chapter 4: DISCUSSION        Low Dose CO and Cardiac IR injury
ventricular myocardium.  This regional variation seen with focal infarcts occurring following coronary 
occlusion  are  different  to  the  pathology  described  in  earlier  papers  studying  globally  infarcted 
myocardium (Jayakumar et al., 2000; Sammut et al., 2001). Unfortunately, due to technical reasons we 
were unable to measure complex IV activity in our laboratory. CO inhibits complex IV and this effect 
is responsible for some of its toxic effects (Alonso et al., 2003), however we speculated that at this low 
concentration it is unlikely to have a significant effect on this enzyme complex, in fact it may have 
contributed to preconditioning and prevention of apoptosis by the release of small amounts of ROS 
(Zuckerbraun et al., 2007; Kondo-Nakamura et al., 2010; Queiroga et al., 2010).
These results do not correlate with other investigators who have demonstrated reduction in complex I, 
III and IV in response to IR injury (Ide et al., 2001; Chen et al., 2007). It is possible that the IR injury 
was not sufficient to cause measurable changes in these values, however this would be out-of-keeping 
with the results of other parts of the study and may be due to technical issues. Unfortunately, there was 
not enough isolated mitochondria remaining after the initial experiments to be able to repeat the whole 
batch.
We administered CO both before and after IR injury to simulate the clinical scenario of a patient who is 
being prepared for elective cardiac surgery when there is ample opportunity to pre-medicate to reduce 
the IR injury associated with this procedure. The rat model has an exaggerated ischaemic insult as may 
occur in cases where there has been inadequate cardioprotection. Potential limitations of the model are 
that the experiments were performed in young animals who have not developed atherosclerosis and 
ischaemic heart  disease. As highlighted in the introduction,  the development  of atherosclerosis  and 
ischaemia involves a complex interplay of biochemical, physiological and pathological processes that 
may influence many of the end points measured in this study. For example, cytokines are intimately 
involved in the development of atherosclerosis, acute and chronic ischaemia and reperfusion injury so 
using this model to try to accurately predict the effects of CO in patients who have advanced heart  
disease may not be entirely accurate. It is well known that young patients who present with sudden 
coronary  artery  occlusion  due  to  an  embolus  or  coronary  artery  dissection  fare  much  worse  than 
patients who have already well established coronary artery disease and then develop occlusion due to 
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plaque rupture and thrombosis. This is largely due to the presence of collateral circulation and the up-
regulation of cellular cytoprotective mechanisms with the development of a “hibernating” myocardium 
(Cohen and Rentrop, 1986; Ware and Simons, 1997; Depre and Vatner, 2007; Depre et al., 2010). How 
much additional benefit CO would confer is unclear from this study.
Another potential criticism of the study is centred on the toxic nature of CO. There can be no argument 
with the fact that high doses of CO cause hypoxia and tissue ischaemia. Ischaemic preconditioning by 
non-lethal  ischaemia  prior  to  a  larger  ischaemic  insult  has  been  an  area  of  intensive  research. 
Physiological processes involved in ischaemic preconditioning involve induction of hypoxia inducible 
factor (HIF) and erythropoetin  (Loor and Schumacker, 2008). CO exposure to macrophages in cell 
culture causes a burst of ROS leading to an increase in HIF and subsequently the anti-inflammatory 
cytokine transforming growth factor beta (TGF-β) (Chin et al., 2007). In counter argument, the doses 
used were much higher (250ppm) and it was not an in vivo experiment. 
A potential hurdle to using CO as a therapeutic agent is its inherent perception as a toxic, noxious gas. 
Most  physicians  have  treated  CO  poisoning  at  some  time  during  their  career  and  changing  their 
perceptions  and  more  importantly  the  patients'  understanding  of  this  gas  could  be  challenging. 
Paracelsus, the Renaissance physician and founder of toxicology intuitively pointed out in the 16th 
century that “all substances are poisons, there is none that is not a poison: the correct dose differentiates 
a poison from a remedy”. This philosophy and the results of our study and many others may help to 
change preconceived ideas.  CO releasing molecules  (CORM) are being developed using transition 
metal carbonyls which may make the compound more palatable, and easier to administer (Motterlini et  
al., 2002). The low dose (20ppm) used in our in-vivo study would be unlikely to have any toxic effect,  
as evidenced by the very modest rise in COHb levels. An interesting area for future study is to examine 
the  relationship  between  statins  and  the  heme  oxygenase  pathway  and  its  intermediates,  CO and 
biliverdin which has so far only been the subject of limited cell based studies  (Grosser  et al., 2004; 
Chen et al., 2006). 
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In conclusion,we have shown that low dose inhaled CO exerted cardioprotective effects in an IR injury 
model, as measured by heart rate, LVDPmax, coronary artery flow, and to a lesser extent diastolic 
function.  From  our  experiments,  the  protective  effect  may  have  been  caused  by  CO's  ability  to 
modulate the cytokine response to inury, most specifically increasing the IL10 / TNF-α ratio which is 
associated  with  improved  outcomes  in  cardiac  IR injury.  Cardiac  mitochondrial  energetics  proved 
difficult to analyse within focal peri-infarct tissue undergoing varying stages of cell death and this may 
have contributed to the variation in response within the study groups, however CO tended to increase 
Complex I activity in sham interventions at 1 and 28 days. No detrimental effects to inhaled CO at 
20ppm were observed and COHb levels did not reach toxic levels. Chronic intervention with CO gas 
exposure following IR injury maintained cardioprotection over the healing phase and is superior to air 
exposure  alone  and  also  short  term CO exposure  (1  day before  and  1  day after  IR injury)  when 
outcomes were measured at 28 days. 
Therefore we suggest that low dose CO may offer both short and long term cardioprotective benefits 
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